In this JCO Article Insights episode, Rohit Singh provides a summary on “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data", by Long et al, published in the November issue of the Journal of Clinical Oncology. The article provides insights into the use of the two dual immune checkpoint inhibitor regimens in patients with untreated advanced melanoma.
All Melanoma News
Tumor characteristics found to differ for melanomas in children, teens and young adults
Tumor characteristics differ significantly among pediatric and adolescent and young adult (AYA) patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma, according to a study published online Nov. 15 in the Journal of the American Academy of Dermatology.
FDA Receives BLA for RP1 and Nivolumab Combo in Advanced Melanoma
The FDA has received a BLA submission seeking the accelerated approval of RP1 plus nivolumab for the potential treatment of adult patients with advanced melanoma who have received prior treatment with a regimen that contains a PD-1 inhibitor.
Characteristics Differ for Melanomas in Children, Teens, Young Adults
TUESDAY, Nov. 26, 2024 (HealthDay News) — Tumor characteristics differ significantly among pediatric and adolescent and young adult (AYA) patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma, according to a study published online Nov. 15 in the Journal of the American Academy of Dermatology.
Heart Transplant Recipients are More Susceptible to Skin Cancer
Certain factors may contribute to higher occurrences of non-melanoma skin cancer in these patients, according to a novel systemic review.
Predictive tool for melanoma could guide immunotherapy choices
Summary: In previous research, Dana-Farber researchers found that a tumor’s genomic heterogeneity, meaning the tumor’s propensity to develop new mutations, and low genomic ploidy, a measure of the number of chromosomes in the cells, predicts resistance to immune checkpoint blockade with anti-PD-1 therapy.
10-Year Survival Rates Near 80% for Melanoma Patients Responding to Checkpoint Inhibitors
Two sets of 10-year outcome data from large multicenter trials with checkpoint inhibitors for the treatment of advanced melanoma found that more than 40% of treated patients survive 10 years overall, but the 10-year melanoma-free survival approaches 100% in those with a deep response who remain in progression-free survival (PFS) at three years.
HBI-8000 Plus Nivolumab Is Safe, Active in Melanoma
The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no prior anti–PD-1/PD-L1 treatment.
Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma
The FDA received a biologics license application for the accelerated approval of RP1 (vusolimogene oderparepvec) plus nivolumab (Opdivo) to treat adults with with advanced melanoma that was previously treated with a PD1 inhibitor.
Unexpected Findings in Study of T Cells, Considered Front-line Fighters Against Advanced Melanoma
Yale researchers made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma that was published Nov. 28 in Nature Immunology.
Immune Cell Breakthrough: Scientists Discover a Hidden Ally in the Fight Against Cancer
Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to potential strategies to enhance treatment efficacy and overcome resistance.
New Clinical Pathway Supports Cancer Recurrence Anxiety
Researchers have developed a three-step plan to support those burdened by the intense fear of cancer returning. This plan offers a consistent, streamlined approach to managing recurrence anxiety, empowering patients to regain confidence and move forward with their lives.
Unexpected Findings in Study of T Cells Considered Front-Line Fighters Against Advanced Melanoma
Newswise — Yale researchers made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma that was published Nov. 28 in Nature Immunology.
Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy
Panelists discuss how treatment decisions in metastatic melanoma involve balancing the benefits of immunotherapy versus targeted therapy, taking into account factors such as tumor genetics, patient response, and tolerability
Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma
Panelists discuss how the RELATIVITY-047 trial data highlights the efficacy of nivolumab plus relatlimab in managing advanced melanoma, offering improved progression-free survival with a favorable safety profile compared to with nivolumab alone.
Tumor-targeted responsive nanoparticles for MRI and therapy
Manganese oxide nanoparticles (Mn3O4 NPs) were synthesized and modified with an LHRH-targeting peptide or anti-melanoma antibodies (cancer-targeting moieties), as well as an MMP2 cleavable peptide (a possible chemotactic agent). Nanostructured lipid carriers (NLCs) were employed to entrap the BRAF inhibitor vemurafenib and enhance the drug’s cytotoxicity.
Predictive Tool for Melanoma Could Guide Immunotherapy Choices
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.
New Study Identifies Effective Treatments for Melanoma-Associated Leptomeningeal Disease
In an interview, Vincent Law, of Moffitt Cancer Center, discussed a new study that offers hope for patients with melanoma brain metastasis.
New Discovery on Protein Interaction and Proliferation of Melanoma
Melanoma that proliferates from pigment-producing melanocytes is the deadliest form of skin cancer, which can be caused by extensive ultraviolet light exposure, especially in individuals with low levels of melanin. A
NICE Recommends Tebentafusp Reimbursement for HLA-A*02:01+ Uveal Melanoma
NICE has recommended the reimbursement for tebentafusp in HLA-A*02:01–positive unresectable or metastatic uveal melanoma.
Considering the Changing Treatment Landscape for Patients With Melanoma
Evan Lipson, MD, an associate professor of oncology at John Hopkins School of Medicine and a head and neck oncologist at John Hopkins Medicine, discusses the evolving treatment landscape for advanced melanoma.
Dabrafenib-Trametinib Combo Shows Activity as Second-Line Adjuvant Therapy in Advanced Melanoma
Second-line adjuvant treatment with dabrafenib and trametinib appeared effective in a small study of patients with BRAF V600-mutated, resected, stage III/IV melanoma, researchers found. In fact, more than 80% of patients were free from relapse and metastasis at 1 year. These results were published in The Oncologist.
Study identifies ‘turncoat’ cells that fight—and aid—cancer
Yale researchers have made an unexpected discovery—turncoat T cells that help a tumor evade other cancer-fighting immune T cells—in a study of patients living with advanced melanoma.
RP1 and Other Oncolytic Viruses Could Pave a New Treatment Pathway in Advanced Melanoma
Bently P. Doonan, MD, discusses the utility of oncolytic viruses and the need for novel treatments after checkpoint inhibitors in advanced melanoma.
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
On December 20, 2024, the U.S. Food and Drug Administration granted accelerated approval to encorafenib (Braftovi) in combination with cetuximab and modified fluorouracil, leucovorin,
Dissecting Ongoing Research With Oncolytic Viruses in Melanoma
Elizabeth Buchbinder, MD, discusses the implications of the FDA’s decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.
New Cancer Vaccines on the Horizon: Renewed Hope or Hype?
Vaccines for treating and preventing cancer have long been considered a holy grail in oncology.
Melanoma Density Is Greater in Upper Body Regions Than Lower Body Regions
A significant vertical gradient in cutaneous malignant melanoma density has been identified, as melanoma density is notably higher in upper body regions like the face and ears than in lower body areas. Published in Skin Health and Disease, the study findings highlight the need for targeted sun protection strategies, particularly for high-risk areas frequently exposed to sunlight.
Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma
Panelists discuss how dual immunotherapy for melanoma, including combinations like nivolumab plus ipilimumab or nivolumab plus relatlimab, requires careful consideration of sequencing decisions based on factors such as tumor burden, patient health status, and potential toxicity profiles.
UV and Outdoor Sports: The Importance of Coaches in Educating Athletes
Despite the risks of sun exposure, a study found only a fraction of coaches receive adequate UV-related guidance from their associations or clubs.
Melanoma Patients’ Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
ATLANTA — Researchers at the University of California San Francisco report that melanoma patients whose cancer has spread to their sentinel lymph nodes (SLNs) have a greater chance of experiencing disease recurrence and mortality compared to those whose cancer has not advanced to their SLNs.
The Spot sends a message to Australians about skin cancer and melanoma
Bristol Myers Squibb is proud to have partnered with La Roche-Posay, Ogilvy and Sculpture by the Sea on The Spot to highlight to Australians that prevention and early disease detection is the best way to tackle skin cancer and melanoma.
Melanoma Mortality Rises at 0.8-mm Breslow Thickness, Study Finds
The risk for melanoma-related death was higher in individuals with tumors with a Breslow thickness of 0.8-1.0 mm than in individuals with tumors smaller than 0.8 mm, in an Australian study that used registry data.
2024 Breakthroughs in Skin Cancer
Discover 2024 skin cancer breakthroughs, including FDA approvals, innovative therapies, and updated clinical guidelines for melanoma and nonmelanoma care.
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
Many earlier ctDNA studies in melanoma utilized technologies that target a narrow spectrum of recurrent driver alterations, an approach that limits application in patients with tumors lacking BRAF and NRAS mutations. In contrast, the study successfully identified ctDNA in patients with tumors lacking BRAF and NRAS mutations, suggesting that this tumor-informed approach may be informative in a wider range of patients.
Dr Doonan on Treatment Strategies Following Progression on ICIs in Advanced Melanoma
Bently P. Doonan, MD, clinical assistant professor, Division of Hematology & Oncology, Department of Medicine, College of Medicine, the University of Florida, discusses current strategies for and associated challenges with the treatment of patients with advanced melanoma following disease progression on immune checkpoint inhibitors (ICIs).
Radioactive Iodine Therapy in Thyroid Cancer May Increase Melanoma Risk
Patients with primary thyroid cancer who received radioactive iodine therapy have elevated risks for melanoma and other nonkeratinocyte skin cancers, according to study findings published in JAMA Network Open.
FDA Grants Fast Track Designation to IMM-1-104 for Advanced Melanoma
The FDA granted a fast track designation to IMM-1-104 (Immuneering Corp.) to treat patients with unresectable or metastatic NRAS-mutant melanoma whose disease progressed or is intolerant to PD-1-/PD-L1-based immune checkpoint inhibitors.1 Currently, the treatment is undergoing evaluation in a phase 2a clinical trial (NCT05585320)2, which enrolled patients with advanced solid tumors, including melanoma.
Does Indoor Tanning Affect Melanoma Tumor Mutational Burden?
Indoor tanning exposure was not associated with tumor mutational burden (TMB) in patients with cutaneous melanoma, in a retrospective cohort study. Higher TMB was linked to older age, head and neck tumors, and a history of nonmelanoma skin cancer (NMSC).
Medical mismanagement may contribute to worse survival outcomes for invasive melanoma
Patients with upstaged tumors saw an overall mortality rate of 36% vs. 19.5% in their non-upstaged counterparts.
Melanoma survival linked to tumor thickness
Researchers at The University of Sydney have identified a significant increase in melanoma-related death risk for patients with thin primary tumors measuring between 0.8 and 1.0 millimeters compared to those with thinner lesions.
A model to predict iris melanoma
Arun Singh, MD, and colleagues developed a model that provides direct diagnostic prediction of a lesion being iris melanoma. He is Director of the Department of Ophthalmic Oncology, Cole Eye Institute at the Cleveland Clinic, Cleveland Clinic Main Campus Hospital, Cleveland.
Novel immunotherapy combo shows promise in melanoma
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical trial led by the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute (NCI).
Success in First Real-World Case of Relatlimab Combo for Treatment of Conjunctival Melanoma
With recent interest in immunotherapy on the rise, researchers led by Mirona Attrash treated an older patient presenting with invasive conjunctival melanoma who elected to bypass surgery with the combination of relatlimab-nivolumab (anti-PD-L1/anti-LAG3 inhibitors).
Opdivo and Yervoy May Improve Survival for Resected Stage 3/4 Melanoma
Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates compared to those treated with placebo.
Global research team develops diagnostic model for iris melanoma
Investigators from Bergen, Norway, and Cleveland, Ohio, collaborated on the predictive model
Radioactive iodine for thyroid cancer linked to risk for melanoma, other skin cancers
Patients with primary thyroid cancer who received radioactive iodine therapy had elevated risk for melanoma/skin cancer.
Watch the melanoma sculpture The Spot growing on Tamarama beach
The artwork The Spot, by Andrew Hankin, on Tamarama beach during the 2024 Sculpture by the Sea exhibition in Sydney, Australia.
The scientist who tested his revolutionary medicine on his own brain cancer: ‘It seemed worth it to give it a crack’
Richard Scolyer was fully engaged in the business of living when he suddenly received a death sentence. A person more alive would be hard to find. As an endurance athlete competing across the globe, he was in peak physical condition. As one of the world’s leading pathologists on melanoma whose pioneering research has saved thousands of lives, he was in demand. At 56, Prof Richard Scolyer was flying along. His life, he says, was “rich”. And then, on the morning of 20 May 2023, he found himself losing consciousness and convulsing on the floor in a hotel room in Poland, panicking and scared.
Immunotherapy Combination May Demonstrate Benefit in Patients With Cutaneous Melanoma
Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve tumor control in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell.
Latest data reveals NSW’s top melanoma hotspots
The Cancer Institute NSW’s newly released melanoma hotspot map reveals Ballina, Lismore, Byron, Clarence Valley and Coffs Harbour local government areas (LGAs) have the state’s highest rates of melanoma, with almost 350 cases projected to be diagnosed in those areas in 2024.
Wide local excision, Mohs remain primary treatment options for positive tumor margins
Positive margins are infrequent following standard excision, but when they do occur it is mostly in the upper extremities.
Quick Chat About Skin Cancer with Yale Dermatologist Sean Christensen
Skin cancer is the most common type of cancer in the United States, with millions of cases diagnosed each year. According to the National Institutes of Health (NIH), basal cell carcinoma and squamous cell carcinoma are the most frequently occurring forms, with over 4 million and 1 million cases annually, respectively.
First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma
Oslo, Norway, November 6, 2024 – Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, announces that the first patient has been treated in a new Phase II trial (NeoLIPA). The study evaluates the effect of Lytix’s lead drug candidate, LTX-315, in early-stage patients diagnosed with melanoma. Melanoma is the most severe type of skin cancer with a rising incidence globally and an estimated global market of USD 11 billion by 2030.
Heart Transplant Recipients May Have a Significantly Higher Melanoma Risk
Patients who have received a heart transplant have a significantly increased risk for melanoma compared with the general population, according to study results published in Melanoma Research.
Study links tanning bed use to rising melanoma rates in New England
Melanoma accounts for only 1% of skin cancers in the United States but results in the largest number of skin cancer deaths. Investigators evaluated the potential link between the availability and use of tanning beds and the rising rates of melanoma in New England. They found compelling evidence linking tanning bed usage to increased melanoma risk. Their spatial epidemiologic study in the Journal of Investigative Dermatology, published by Elsevier, provides critical insights to inform public health strategies and reduce melanoma incidence.
Dr. John Fruehauf on a New Standard of Care for Stage III Melanoma
Dr. John Fruehauf, field medical director at Evolent, and specialist in melanoma, spoke to DocWire News about some of the challenges associated with treating melanoma in stage III disease, and about the NADINA trial, which demonstrated the robust efficacy of neoadjuvant nivolumab in combination with ipilimumab in the treatment of stage III melanoma. The trial findings, which Dr. Fruehauf details, represent a new standard of care in melanoma.
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
Radiomic biomarkers can be leveraged to predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib (IOA-244), according to findings from a study that were presented at the 2024 SITC Annual Meeting.
Cutaneous malignant melanoma incidence increasing among the elderly
From 1987 to 2016, there was a considerable increase in the incidence of cutaneous malignant melanoma (CMM) among the elderly in the United States, according to a study published online Oct. 28 in Cancer Screening and Prevention.
Travel Time to Tanning Facilities Negatively Linked to Melanoma Incidence
THURSDAY, Nov. 7, 2024 (HealthDay News) — There is a negative association between travel time to tanning facilities and county-level melanoma incidence rates, according to a study published online Nov. 7 in the Journal of Investigative Dermatology.
IMA203 Shows Frequent, Enduring Responses and Tolerability in Melanoma
Phase 1 data highlight a manageable safety profile with IMA203 among patients with melanoma and other PRAME-positive solid tumors.
Risk Factors for Skin Tumors, Melanoma Vary for Patients With Parkinson Disease
Investigators in Israel compared rates of risk factors for CMM, non?melanoma skin cancer (NMSC), and actinic keratosis (AK) among individuals with and without PD.
Sunscreen doesn’t cause melanoma; most melanoma cases are due to excess UV radiation from the sun
Factually inaccurate: The first medical descriptions of melanoma predate the invention of sunscreen. Scientific evidence shows that sunscreen reduce the harmful effects of UV radiation in sunlight, thereby reducing skin cancer risk.
Data Support Siglec-15 as Possible Signal in NSCLC and Other Solid Tumors
Detection of S15 and PD-L1 proteins in more than half of NSCLC samples support the potential to target both pathways during treatment.
Ashfaq Marghoob, MD: Identifying Dermoscopic Patterns in Facial, Palmoplantar, Nail, and Mucosal Lesions
Marghoob shares key dermoscopic features to help clinicians identify benign vs malignant lesions on various locations of the body.
IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors
The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,
RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy
RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.
Novel Combo Shows Early Activity in PD-L1–Resistant NSCLC, Melanoma
Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.
Retrospective Analysis Across Six CheckMate Trials Reinforces Benefit of Nivolumab Plus Ipilimumab
A pooled analysis of six CheckMate studies in immune checkpoint inhibitor (ICI), specifically treatment with nivolumab plus ipilimumab (NIVO + IPI) versus NIVO monotherapy, aimed to describe the long-term overall survival in patients with ICI treatment-naïve unresectable/metastatic melanoma.
From melanoma to malaria: photoacoustic device detects disease without taking a single drop of blood
Malaria remains a serious health concern, with annual deaths increasing yearly since 2019 and almost half of the world’s population at risk of infection.
Vidutolimod Plus Nivolumab Proves Active in High-Risk, Resectable Melanoma
The combination of vidutolimod and nivolumab demonstrated activity in a phase 2 trial of patients with high-risk, resectable melanoma, according to researchers. They reported these findings in Cancer Cell.
TIL Therapy Uses the Body’s Own Cells to Attack Cancer Cells in Melanoma
Tumor-infiltrating lymphocyte (TIL) therapy is a promising new approach to cancer therapy that harnesses the body’s own immune system to treat diseases like melanoma, a type of skin disease, an expert said.
Yeppoon family shares devastating melanoma journey in hope it saves lives
Lyell Duffy thought he had pulled a muscle at work when he began experiencing back pain.
Low Neutrophil-Lymphocyte Ratio Linked to Better Survival in Some Melanoma Cases
Baseline neutrophil-lymphocyte ratio (NLR) is a significant predictor of disease progression and overall survival (OS) in patients with metastatic melanoma undergoing programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) blockade therapy, according to study results published in Melanoma Research.
Dr Moreno on the Pharmacodynamics of CLN-619 in Advanced Solid Tumors
Victor Moreno, MD, PhD, medical oncologist, director, Clinical Research, START Madrid-Fundación Jimenez Diaz (FJD), discusses insights into the pharmacodynamic data for CLN-619, a novel humanized IgG1 antibody designed to bind to MICA and MICB, in patients with advanced solid tumors. Findings were presented by Moreno and colleagues during the 2024 SITC Annual Meeting.
Moffitt Study Shows Immune Structures in Melanoma Could Help Predict Patient Survival
TAMPA, Fla. — A new study has found that certain immune structures may be linked to better survival in patients with melanoma, the deadliest form of skin cancer. The study, led by researchers at Moffitt Cancer Center in collaboration with investigators at UPMC Hillman Cancer Center, was published in the Journal for ImmunoTherapy of Cancer.
Addressing Pros and Cons of CAR-T Cell Therapy in Melanoma
For patients with melanoma, treatment with CAR-T cell therapy may come along with pros and cons to consider.
Remote Telemedicine Tool Found Highly Accurate in Diagnosing Melanoma
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.
Immunotherapy Combination for Cutaneous Melanoma
Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve outcomes in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell.
MyMelanoma study selected to join NHS DigiTrials initiative
Three projects – including the Oxford-led MyMelanoma study – have been selected to join an NHS initiative, which aims to sign up tens of thousands of volunteers over the next two years to help improve the diagnosis and treatment of cancer patients.
Sunday Brunch with Professor Richard Scolyer AO
Simon visits Australian of the Year 2024 and co-medical director at the Melanoma Institute Australia Professor Richard Scolyer AO for Sunday Brunch.
What Is Known About Psychosocial Wellbeing in Patients With Melanoma In Situ?
A significant gap in research on psychosocial wellbeing among patients newly diagnosed with melanoma in situ (MIS) exists, according to the results of a systematic review published in Melanoma Research.
Lymphoid Aggregates as Positive Prognostic in Overall Survival for Melanoma
Because the prevalence and impact of immature precursor lymphoid structures known as lymphoid aggregates (LAs) remain unresolved in relation to metastatic cutaneous melanoma disease progression, researchers examined the characteristics and prognostic ability of LAs and tertiary lymphoid structures (TLSs) in histologic samples from patients with melanoma.
In-Person Exam With Dermoscopy Yields More Accurate Skin Cancer Diagnosis
Accuracy in diagnosing skin cancer varies depending on the examination method used and on the physician’s specialty and experience level, according to research published in JAMA Dermatology.
Overall melanoma incidence decreasing among young patients
The incidence rates per 1 million person-years among pediatric and adolescent/young adult patients were 1.74 and 62.05.
Oncologists Experience Improved Survival in Patients With Melanoma
Evan Lipson, MD, an associate professor of oncology at John Hopkins School of Medicine and a head and neck oncologist at John Hopkins Medicine, discusses feedback he’s received from colleagues at Case-Based Roundtable events about patients with melanoma.
UVA Heath begins new clinical trial to battle deadly melanoma
CHARLOTTESVILLE, Va. (WRIC) — A research team at UVA Health System is pioneering a new approach to treating melanoma, one of the deadliest forms of skin cancer.
Scientists identify key mechanism in development of skin cancer
Melanoma arising from pigment-producing cells known as melanocytes is the deadliest form of skin cancer. A major cause of melanoma is excessive exposure to ultraviolet light, from sunlight or other sources, which can trigger mutations that promote tumor formation.
Blue Eye Color May Be Linked With Greater Uveal Melanoma Risk and Poorer Prognosis
A retrospective study based in the Netherlands found an apparent genetic link between blue eye color and poorer survival in patients with uveal melanoma—including a greater incidence of high-risk tumor development in patients with light eyes than in those with darker eyes—though larger, more diverse studies are needed to confirm these findings.
Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma
In a pooled analysis of long-term outcomes reported in the Journal of Clinical Oncology, Long et al found that nivolumab plus ipilimumab was associated with better overall survival vs nivolumab monotherapy in immune checkpoint inhibitor treatment–naive patients with unresectable or metastatic melanoma.
Cutaneous Melanoma Incidence Declining Among Pediatric, AYA Patients
The incidence of cutaneous melanoma is generally declining among pediatric and adolescent and young adult (AYA) patients in the United States, according to research published in the Journal of the American Academy of Dermatology.
Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma
A biologics license application was submitted to the FDA seeking the accelerated approval of RP1 (vusolimogene oderparepvec) plus nivolumab (Opdivo) for the treatment of adult patients with advanced melanoma who have received prior treatment with a regimen containing a PD1 inhibitor. The combination also received breakthrough therapy designation from the FDA for the same designation.
Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction
Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.
Scientists identify key mechanism in development of skin cancer
LMU researchers have discovered how the interplay between a key protein and an endolysosomal ion channel promotes tumor development in skin cancer.
New Study May Help Refine Sentinel Node Biopsy Decisions for Melanoma Patients
A new study presented at the Society for Melanoma Research annual meeting could influence how early-stage melanoma patients are selected for sentinel node biopsy, a surgical procedure often used to determine if melanoma has spread to the lymph nodes.
Towards evidence-based skin checks
Although melanoma is often referred to as Australia’s national cancer, an organised screening program is recommended for cost effectiveness and diagnosis.
SkylineDx Announces Data from Largest Prospective Multi-Center Melanoma Gene Expression Profiling Trial at 21st International Congress of the Society for Melanoma Research
The Merlin test (CP-GEP) stratifies melanoma patients based on risk for sentinel lymph node (SLN) metastasis, offering a powerful tool for risk-based decision-making.
Fianlimab Combo Shows Activity in Advanced Melanoma Subtypes
The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.
PRAME-Targeted Agent Shows Activity in Pretreated Metastatic Melanoma
Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.
Scientists Use CRISPR Tools to Safely Disable Gene Mutation Linked to Advanced Skin
In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of this dangerous skin cancer that renders promising treatments ineffective.
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy.
Melanoma Risk Doubled for Monoclonal B-Cell Lymphocytosis
Patients who have the low-count chronic lymphocytic leukemia (CLL) phenotype monoclonal B-cell lymphocytosis (LC-MBL) have a nearly doubled risk for melanoma, according to a study in Journal of Clinical Oncology.
Study Highlights Racial Differences in Second Primary Melanoma
White patients have the highest absolute risk for a second primary melanoma, while Black and Asian or Pacific Islander patients have the highest relative risk compared with the general population, a study analyzing Surveillance, Epidemiology, and End Results (SEER) data report.
Gene editing restores treatment sensitivity in melanoma
In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of this dangerous skin cancer that renders promising treatments ineffective.
Black Patients Have the Highest Mortality Risk For Melanoma of the Head and Neck
Black patients have the highest disease-specific mortality risk among patients with cutaneous melanoma of the head and neck, according to study findings published in the Journal of the American Academy of Dermatology.
SkylineDx Data Confirms Accuracy of the Merlin Test for Low- and High-Risk Melanoma
Results from Society for Melanoma Research Congress demonstrated excellent predictive power of noninvasive CP-GEP Merlin test.
Melanoma cells use apolipoprotein E to evade ferroptosis, study finds
A research team led by Prof. Patrizia Agostinis (VIB-KU Leuven) has found that melanoma cell populations protect themselves from a form of cell death called ferroptosis by secreting the lipoprotein apolipoprotein E (ApoE). Their work appears in Science Advances.
Head and Neck Melanoma: Clinicopathologic Profile Is Worse Than Other Melanomas
Cutaneous head and neck melanoma (CHNM) has a worse clinicopathologic profile compared with cutaneous melanomas from other sites (CMOS), according to study findings published in the Journal of the American Academy of Dermatology.
Researchers awarded $5m NHMRC Synergy Grant to improve immunotherapy against melanoma
A collaborative team of researchers, including researchers from the Doherty Institute, has been awarded a five-year, $5 million Synergy Grant?from the?National Health and Medical Research Council (NHMRC) to develop a new program of work, exploring interactions between microbiota and T cells to enhance melanoma immunotherapy.
Texas A&M Researchers Explore Light And Ultrasound Therapy For Melanoma Treatment
Texas A&M University researchers are collaborating on a new project that studies how ultrasound and light can treat melanomas in pigs.
Richard Scolyer didn’t expect to be still alive. Now he’s meeting the King
Professor Richard Scolyer did not expect to be alive now.
Chloe Morello’s plea to Aussie families: check your skin
Throughout my life, skin cancer has been an unwelcomed guest in my family.
How Melanoma Cells Escape Oxidative Stress to Metastasize
Researchers have discovered how some melanoma cells defend against oxidative stress and metastasize to new organs.
Wide Local Excision May Not Be Useful for Improving Malignant Melanoma Prognosis
Wide local excision (WLE) may not provide significant clinical benefits for patients with early-stage malignant melanoma and Breslow thickness may be the only independent predictive factor, potentially leading to overtreatment and associated complications. These study results were published in Melanoma Research.
Melanoma Incidence Increased Globally During Last 30 Years
The global burden of melanoma increased significantly from 1990 to 2021, according to study findings published in the Journal of the American Academy of Dermatology.
Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in Melanoma Care
ROTTERDAM, Netherlands and SAN DIEGO, Oct. 24, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announced today the results of a comprehensive systematic review and meta-analysis conducted by Melanoma Institute of Australia (MIA).
National targeted skin cancer screening to be accelerated with $10.3 million investment
The Albanese Government is investing $10.3 million to tackle the most common cancer in our sunburnt country, skin cancer.
Elderly population faces escalating melanoma incidence over three decades
The prevalence and fatality rates of cutaneous malignant melanoma (CMM) have been rising, particularly among the elderly.
MMS-I Treatment Is Linked to Low Recurrence, Mortality in Head and Neck Melanoma
Mohs micrographic surgery with melanocytic immunostains (MMS-I) is emerging as an effective treatment option for invasive melanomas, particularly in anatomically constrained areas, due to a low risk of local recurrence and disease-specific mortality, according to study results published in Dermatologic Surgery.
Art meets sun safety: ‘The Spot’ sculpture aims to raise melanoma awareness at Bondi
A growing melanoma sculpture, ‘The Spot’, is currently on display at Sculpture by the Sea, Bondi. The sculpture, which began at around five metres and continues to expand to over 20 metres wide, was created by two creatives from Ogilvy Health, in collaboration with The Glue Society and The Beautiful and Useful Studio.
Impact of Malignant Melanoma on Employment and Work Ability
The study underscores the importance of addressing work-related concerns for patients with melanoma, advocating for effective communication about rehabilitation options.
Tumor-Infiltrating Lymphocyte Therapy Tackles Treatment Blind Spot in Advanced Melanoma
Treatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.
Longer Time Until Recurrence Associated With Better Melanoma Outcomes
An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved progression and survival.
Anti-CTAg Antibodies Identified in Stage I, II Melanoma
WEDNESDAY, Oct. 2, 2024 (HealthDay News) — Circulating antibodies against cancer-testis antigens (CTAgs) are found in stage I and stage II melanoma plasma samples, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25 to 28 in Amsterdam.
Anti-Cancer Antibodies May Aid Early Melanoma Detection
Australian researchers have shown that circulating antibodies against tumor antigens can be used as an accurate biomarker for the early detection of melanoma.
Anti-CTAg Antibodies Identified in Stage I, II Melanoma
HealthDay News — Circulating antibodies against cancer-testis antigens (CTAgs) are found in stage I and stage II melanoma plasma samples, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25 to 28 in Amsterdam.
Study Looks at Sex Differences in Melanoma Incidence
HealthDay News — Melanoma rates differ for men and women, including in terms of ages of occurrence and locations of melanoma, according to a study published online June 17 in the Journal of Investigative Dermatology.
Immunotherapy saved my life. Can research improve the odds for others?
Alex Green is clear – without immunotherapy, he would have died in 2019.
Microbiotica initiates subject dosing in Phase Ib melanoma therapy trial
Microbiotica has dosed the first subject in the Phase Ib MELODY-1 clinical trial of MB097, a precision microbiome co-therapy targeting advanced melanoma.
Dr Truong on Targeted Therapy vs Immunotherapy in BRAF V600–Positive Melanoma
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic, discusses long-term findings from the phase 2 ImmunoCobiVem trial (NCT02902029) investigating early switch from targeted therapy to immunotherapy in patients with advanced BRAF V600–positive melanoma.
Melanoma with Drug Resistance: Cause Identified
Newswise — Melanoma is a type of cancer that originates from melanocytes, the cells responsible for producing skin pigment, and is known as the most lethal form of skin cancer due to its high rates of metastasis and recurrence. With the global trend of aging populations, the number of melanoma patients is rapidly increasing, and it is projected that by 2040, approximately 100,000 people worldwide will die from melanoma annually. In clinical practice, melanoma is currently treated with targeted therapies that inhibit the BRAF oncogene. However, drug resistance to BRAF inhibitors develops quickly, limiting the effectiveness of these treatments.
Cell line models identify cause of melanoma with drug resistance
Melanoma is a type of cancer that originates from melanocytes, the cells responsible for producing skin pigment, and is known as the most lethal form of skin cancer due to its high rates of metastasis and recurrence. With the global trend of aging populations, the number of melanoma patients is rapidly increasing, and it is projected that by 2040, approximately 100,000 people worldwide will die from melanoma annually.
Breakthrough in understanding melanoma drug resistance
Researchers at the Korea Institute of Science and Technology (KIST) have announced a new discovery in the fight against melanoma. The study, published in the journal Molecular Cancer, reveals a new mechanism behind drug resistance in melanoma and proposes potential strategies to overcome it.
Selective Role for Single-Agent Ipilimumab After Anti-PD-1 Failure in Melanoma
Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall survival (OS) when treated with single-agent ipilimumab (Yervoy), a small retrospective case review showed.
Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity
A melanoma diagnosis increases risk of a second primary melanoma regardless of race or ethnicity, a review of a government database showed.
Risk for Second Melanoma Up for Those With First Melanoma Diagnosis
WEDNESDAY, Oct. 9, 2024 (HealthDay News) — Patients with a first melanoma diagnosis have an increased risk for a second melanoma diagnosis, regardless of race and ethnicity, according to a research letter published online Oct. 9 in JAMA Dermatology.
Incidence and Risk of Second Primary Melanoma Vary by Race/Ethnicity
New data suggest that, among patients with first primary cutaneous melanoma, White patients have the highest absolute risk of second primary melanoma. However, Black and Asian or Pacific Islander patients have the highest relative risk of second primary melanoma when compared to the general population. These data were published in JAMA Dermatology.
RELATIVITY-047 vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy
During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Survival Outcomes in Melanoma May Be Improved by Statin Use (
Statin use may have beneficial effects on overall survival (OS) and
disease-free survival (DFS) among patients with melanoma, according
to results of a systematic review and meta-analysis published in
Melanoma Research.
IMA203 Displays Efficacy in Heavily Pretreated Melanoma
IMA203, a TCR-T agent targeting PRAME, was active and offered meaningful
progression-free survival (PFS) and overall survival (OS) outcomes in patients
with heavily pretreated melanoma, according to updated data from a phase 1b
study (NCT03686124) provided by Immatics NV.
Melanoma Incidence, Mortality Declining in Those Aged 30 to 49 Years
HealthDay News — For adults aged 30 to 49 years, there has been a decline in melanoma incidence and mortality, according to a study published online Sept. 8 in JAMA Dermatology to coincide with the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.
ESMO 2024: More than half of advanced melanoma patients treated with combination immunotherapy survive the disease for at least 10 years
Over half (52 per cent) of people diagnosed with advanced melanoma are now surviving the disease for ten years or more when they receive a combination immunotherapy treatment, according to a study led by researchers at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.
Scancell, PharmaJet sign agreement for melanoma vaccine delivery system
Clinical-stage biopharmaceutical company Scancell has signed a strategic partnership agreement with PharmaJet for the supply of PharmaJet’s needle-free Stratis delivery system for the delivery of Scancell’s advanced melanoma vaccine for both clinical development and commercial use.
Cutaneous Head, Neck Melanoma Has Distinct Clinicopathological Profile
WEDNESDAY, Sept. 18, 2024 (HealthDay News) — Cutaneous head and neck melanoma (CHNM) has a distinct clinicopathological and prognostic profile relative to cutaneous melanomas of other sites (CMOS), according to a study published online Sept. 5 in the Journal of the American Academy of Dermatology.
Assessing New RAF-Directed Drugs in Melanoma
Data from the phase I KN-8701 trial suggest that combining exarafenib, an investigational pan-RAF inhibitor, with the MEK agent binimetinib is a reasonable second-line option for NRAS-mutant melanoma.
Hensin Tsao, MD, PhD: TIL Therapy and Neoadjuvant Treatment for Pigmented Lesions
In this Maui Derm NP+PA Fall session, Tsao discusses the growing trend of TIL therapy and neoadjuvant treatment for pigmented lesions, as well as atypical clinical presentation.
Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF V600–positive melanoma.
Cancer charity welcomes new smartphone app for melanoma patients
The app, being developed by the University of Aberdeen, will help people previously treated for melanoma examine their skin regularly to reduce their anxiety and help catch any recurrence of the disease.
Relatlimab/Nivolumab in Melanoma Improves Brain Metastasis–Free Survival
Ahmad Tarhini, MD, PhD: This was a first-line patient population with untreated metastatic melanoma who were randomly assigned 1:1 to a fixed-dose combination of nivolumab at 480 mg and relatlimab at 160 mg [Opdualag]. This was a fixed-dose single infusion on the study given over 60 minutes.
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib………….
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma (UM) and a successful FDA Type C meeting on registrational trial design for regulatory approval in neoadjuvant UM.
Oncologist explains new treatment for advanced melanoma called tumor-infiltrating lymphocyte therapy
Melanoma is a dangerous form of skin cancer that has the potential to spread to other parts of the body.
Tumour-specific antibodies able to detect melanoma in its earliest stages, new study shows
(Thursday, 26 September 2024, Amsterdam, Netherlands) Innovative research has unveiled promising advancements in melanoma detection, which could significantly enhance diagnosis and prognosis by identifying the disease at its earliest, most treatable stages.
New biomarker profiling enhances early detection of melanoma
Innovative research has unveiled promising advancements in melanoma detection, which could significantly enhance diagnosis and prognosis by identifying the disease at its earliest, most treatable stages.
Melanoma Risk Increased After Radioactive Iodine Treatment for Primary Thyroid Cancer
THURSDAY, Sept. 26, 2024 (HealthDay News) — Patients with primary thyroid cancer who receive radioactive iodine therapy have an elevated risk for melanoma and other nonkeratinocyte skin cancers when limiting the cancer site to the head and neck, according to a study published online Sept. 19 in JAMA Network Open.
Dr McKean on the Efficacy of Fianlimab Plus Cemiplimab in Advanced Melanoma
Meredith McKean, MD, executive committee chair, Melanoma and Skin Cancer Research Program, executive committee chair, BRIDGE Program, Sarah Cannon Research Institute, discusses the rationale for combining fianlimab with cemiplimab-rwlc (Libtayo) in the treatment of patients with advanced melanoma and highlights long-term follow-up data with the combination. Notably, these phase 1 trial (NCT03005782) data were shared at the 2024 ESMO Congress.
The Aged Male TME Promotes Melanoma Invasion and Therapeutic Resistance
Major Finding: Age-associated changes in male fibroblasts induce a phenotypic switch to invasive and resistant melanoma.
TH17 Cells May Serve as Biomarker in Metastatic Melanoma
TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
Skin Cancer Care: A Growing Divide in Australia
Skin cancer is a major cause of illness in Australia.
King Charles set to meet cancer researchers in first major foreign tour since health battle
King Charles is set to meet cancer researchers in his first major foreign tour since his health battle.
Immune Checkpoint Inhibitors Potentially Curative for Melanoma
Ten-year follow up from the CheckMate 067 and KEYNOTE-006 trials confirm that patients with advanced melanoma can achieve durable responses from treatment with the PD1 inhibitors nivolumab and pembrolizumab and that a lack of disease progression at 3 years is strong indicator of long-term survival.
50 million for innovative research into mental health, melanoma and more
The search for a multi-season flu vaccine, better treatment for schizophrenia, and how gut microorganisms may fight off melanoma, are 3 projects sharing in $50 million in health research funding from the Australian Government.
Survival Plateau Observed After ICI Therapy in Advanced Melanoma
Patients with advanced melanoma reach a plateau in survival after treatment with immune checkpoint inhibitors (ICIs), according to real-world data published in JAMA Network Open.
Trial of personalised immunotherapy cancer treatment shows promise on melanoma
David Braund went to his GP in April with a small pimple-like mark on his forehead and a swollen lymph node.
Study finds young Aussies 30 per cent less likely to develop melanoma because of skin tone
More young Australians are less likely to develop melanoma as the country becomes more diversely populated, according to new research.
GPs essential to early diagnosis and treatment of melanoma
As Australian patients begin to spend more time in the sun, the Royal Australian College of GPs (RACGP) has urged patients to organise a skin check with their GP to ensure dangerous skin cancers are detected and treated early.
New report backs SciBase’s melanoma detection AI device
Swedish medical detection company SciBase Holding has seen its artificial intelligence (AI) powered device for detecting melanomas, dubbed Nevisense, validated as part of a consensus report that found it effective in detecting potential cancers.
Postsurgical Keytruda Has Little Impact on Quality of Life in Melanoma
Health-related quality of life among patients with stage 3 melanoma was not significantly affected after receiving postsurgical Keytruda or placebo.
GPs alongside oncologists key for melanoma outcomes
Drug therapies for the treatment of melanoma are advancing, and many now play a role for the treatment of earlier stage disease, according to new research.
FDA Grants RMAT Designation to Novel TIL Therapy OBX-115 in Melanoma
This designation follows the fast track designation that was granted to OBX-115 for the same indication in July 2024.
AMLo Biosciences Gets UKCA Mark for Melanoma Biomarker Test
NEW YORK — AMLo Biosciences said Tuesday that it has received UK Conformity Assessed (UKCA) marking for its AMBLor test for identifying early-stage melanomas at low risk of progression.
Immunotherapy Combination Elicit Waves of Response in Advanced Melanoma
A new algorithm has found that combining immune checkpoint inhibitors bolsters immune response among some patients with advanced melanoma.
Study Characterizes Skin Toxicity With Uveal Melanoma Rx
Nearly 80% of patients with metastatic uveal melanoma experienced skin toxicities with tebentafusp, a targeted immunotherapy, according to a study that also suggests that the presence of skin reactions is associated with improved survival.
Phase 3 Trial of First-Line IO102-IO103/Pembrolizumab to Continue in Advanced Melanoma
The phase 3 IOB-013/KN-D18 trial (NCT05155254) evaluating IO102-IO103 in combination with pembrolizumab (Keytruda) for the first-line treatment of patients with advanced melanoma will continue without modifications following a recommendation from an independent data monitoring committee (IDMC).
FDA Grants Fast Track Designation to VMT01 for Unresectable/Metastatic MC1R+ Melanoma
The FDA has granted fast track designation to the development of the targeted alpha-particle therapy (212Pb) VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma, as well as those who have demonstrated melanocortin 1 receptor (MC1R) expression, Perspective Therapeutics announced in a news release.
Mayo Clinic study finds dysfunctional white blood cells linked to heightened melanoma risk
ROCHESTER, Minn. — About 8 to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition — called monoclonal B-cell lymphocytosis (MBL) — do not experience any symptoms, a new study shows they may have an elevated risk for several health complications, including melanoma, a form of skin cancer. The findings, by Mayo Clinic researchers, are published in a new paper in the Journal of Clinical Oncology.
Study From Researchers at Fox Chase Cancer Center and Johns Hopkins Kimmel Cancer Center Shows Aged Male Fibroblasts Increase Melanoma Treatment Resistance
PHILADELPHIA (September 6, 2024) — In a study published today in the prestigious journal Cell, researchers from Fox Chase Cancer Center and Johns Hopkins Kimmel Cancer Center showed changes that occur with age in male skin fibroblasts contributed to an increase in the spread of melanoma cells and made cancer cells resistant to targeted therapy.
Novel Bispecific Antibody Fusion Protein Earns FDA Fast Track in Melanoma
IBI363 has earned fast track designation from the FDA for the treatment of previously treated unresectable advanced melanoma.
Melanoma Deadlier in Men Due to Age-Related Changes in Their Fibroblasts
The results of newly reported research in human cells and in mice, carried out by scientists at Johns Hopkins Kimmel Cancer Center, suggest that age-related changes in fibroblasts contribute to the development of aggressive, treatment-resistant melanoma in males. The researchers, co-led by Ashani Weeraratna, PhD, the Bloomberg Distinguished Professor, E.V. McCollum Professor, and chair of the department of biochemistry and molecular biology at Johns Hopkins, found that human skin fibroblasts—cells that create the skin’s structure—show age-and sex-specific changes in proliferation and stress response, and that male fibroblasts age faster due to elevated levels of reactive oxygen species (ROS).
UQ professor discusses ‘new technologies’ in melanoma research
The University of Queensland’s Professor Peter Soyer discusses his team’s “new” technology in the melanoma research field.
Why are Tasmanians more likely to experience sunburn?
Recent data shows that Tasmanians are more likely to experience sunburn than other Australians.
Melanoma In Situ of Smaller Size Has Low Recurrence With 5-mm Margin for Excision
Excision with 5-mm margins for melanoma in situ that is less than 10 mm in size on low-risk body sites is associated with a low recurrence rate, according to a study published in JAMA Dermatology.
UV Exposure Continues to Be Linked to Increased Melanoma Incidence in Those With Fair Skin
WEDNESDAY, Sept. 11, 2024 (HealthDay News) — Ultraviolet (UV) exposure remains associated with an increased risk for melanoma in patients with Fitzpatrick skin types I to IV, according to a systematic review and meta-analysis published online Sept. 4 in the Journal of the European Academy of Dermatology and Venereology.
Research Highlights Disparities in Melanoma Knowledge and Care
Melanoma is the 17th most common cancer in the world, with over 300,000 patients diagnosed worldwide in 2022 alone.
Investigating Differences in Melanoma Mortality Based on Demographic Information from 1999-2022 Using CDC Wonder
Melanoma is a malignant type of skin cancer and is the fifth most common type of cancer in the United States.
Tawbi Discusses the Role of Brain Metastases and PD-L1 Status in Melanoma
From the RELATIVITY-047 (NCT03470922) and CheckMate 067 (NCT01844505) trials, what are the most important efficacy and safety data?
Sex Matters in How, When, and Where Melanomas Develop
Melanoma rates differ consistently between men and women in terms of the ages at which melanomas occur and the locations on the body where they occur.
Early Phase I data shows promise for mRNA cancer immunotherapy in advanced solid cancers
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
‘Simple model’ helps identify melanoma recurrence
Appetite change, tiredness, lymph node enlargement, abdominal pain and shortness of breath were common with melanoma recurrence.
Melanoma Treatment Advances: Fianlimab and Cemiplimab Show Promise
A longer-term follow-up of a study evaluating fianlimab, an anti-LAG-3 agent, and cemiplimab (Libtayo), an anti-PD-1 agent, is being presented as a poster at this year’s European Society for Medical Oncology (ESMO) Congress.
Neoadjuvant Immunotherapy Superior to Targeted Therapy in Stage III Melanoma
The standard of care for resectable stage IIIB or greater melanoma has been neoadjuvant therapy, and new data shows that neoadjuvant immunotherapy provides a long-lasting benefit to these patients, particularly if they achieve a major pathological response (MPR), which is a complete response or a near complete pathological response.
Oncology Community Mourns the Loss of Dr Jeffrey S. Weber, 2016 Giant of Cancer Care® Winner
Jeffrey S. Weber, MD, PhD, inductee of the 2016 Giants of Cancer Care® award in Melanoma, has died.
Dr Tarhini on the Combination of High-Dose Bolus IL-2 and CTLA-4 Inhibition in Advanced Melanoma
Ahmad Tarhini, MD, PhD, director, Cutaneous Clinical and Translational Research, leader, Neoadjuvant and Adjuvant Translational Science Program, senior member, Moffitt Cancer Center, Research Institute Departments of Cutaneous Oncology and Immunology; professor, Oncologic Sciences, the University of South Florida Morsani College of Medicine; chair, Scientific Committee, Oncology Research Information Exchange Network (ORIEN); chair, ORIEN ImmunoOncology Research Subcommittee, discusses the rationale for investigating high-dose bolus interleukin-2 (IL-2) plus concurrent low-dose ipilimumab (Yervoy), followed sequentially by nivolumab (Opdivo), in patients with advanced melanoma.
Gene activity predicts severe side effects from melanoma immunotherapy
Adverse effects from immunotherapy treatment in melanoma patients are associated with a distinct pattern of
gene expression, offering the possibility for improved therapeutic strategies.
Beyond the slip and slop for keratinocyte skin cancer
For patients with a high burden of non-melanoma cancers, there is more to prevention than just sun avoidance and regular checks and excisions.
Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma
Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the two regimens: RELATIVITY-047 and CheckMate 067, respectively. No direct comparisons of the regimens in this setting have been reported previously.
Using Polygenic Risk Scores to Stratify Patients Based on Risk of Invasive Cutaneous Melanoma
Polygenic risk scores (PRS) may serve as a viable tool to stratify patients based on their risk of invasive melanoma, according to a study published in JAMA Dermatology.
A newly approved ‘living drug’ could save more cancer patients’ lives
Toni English’s medical team was giddy.
Uveal Melanoma Prognosis and Risk Stratification
For patients diagnosed with uveal melanoma, what is the prognosis and the risk of recurrence?
Unmet Needs and Challenges in Metastatic Uveal Melanoma
Experts discuss unmet needs and challenges faced by patients with uveal melanoma. This program was made possible with support from Immunocore.
WIO 2024: Conditional metastasis-free survival of uveal melanoma based on tumor size category
In this study, the investigators retrospectively analyzed the incidence of metastasis in 8,034 patients with uveal melanoma over a 35-year period based on tumor size category.
Dutch beach restaurants add sunscreen ‘shots’ to menu in fight against cancer
Zand Katwijk doesn’t just serve food and drinks – this beachside restaurant offers “shots” of sunscreen too.
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
A new research paper was published in Oncotarget entitled, “Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma."
New Study: SunSmart May Save 1000 Lives in 20 Years
Cancer Council WA has welcomed a new study showing its SunSmart program is saving money as well as lives.
Skin cancer clinic monitors people at increased risk of melanoma due to hereditary gene mutations
A dedicated Dermatology clinic for people with genetic mutations that can lead to skin cancer is now seeing patients in Charleston in partnership with the Hollings Hereditary Cancer Clinic.
Dysfunctional White Blood Cells Linked to Higher Melanoma Risk
About 8 to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition — called monoclonal B-cell lymphocytosis (MBL) — do not experience any symptoms, a new study shows they may have an elevated risk for several health complications, including melanoma, a form of skin cancer. The findings, by Mayo Clinic researchers, are published in a new paper in the Journal of Clinical Oncology.
VMT01 Earns FDA Fast Track Designation in MC1R-Positive Melanoma
The novel agent VMT01 is designed to target and deliver 212Pb to MC1R-expressing tumors like metastatic melanoma.
Breaking the trend: Sweden sees skin cancer decline in under-50s for first time
The risk of skin cancer, malignant melanoma, now appears to be decreasing in Sweden—at least in those under 50, according to a new study.
Experts Report Moderate Patient Adherence to Melanoma Screening and Surveillance Program
Researchers tailored screening and surveillance schedules to individual risk of patients.
EU and UK approve Microbiome Medicines for advanced melanoma and ulcerative colitis
Microbiotica has received the green light from EU and UK regulatory authorities to start phase 1b studies for its microbiome medicines in advanced melanoma and ulcerative colitis.
Nivolumab Combinations Debated for a Patient With Metastatic Melanoma
During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants considered nivolumab/ipilimumab and nivolumab/relatlimab as options for a patient with metastatic melanoma in the first article of a 2-part series.
Dual Checkpoint Blockade Usurps PD-1 Monotherapy as Gold Standard in Unresectable Melanoma
Updated findings from the phase 2/3 RELATIVITY-047 trial (NCT03470922) showing sustained responses and favorable survival outcomes with nivolumab (Opdivo) plus relatlimab-rmbw (Opdualag) in previously untreated patients with metastatic or unresectable melanoma signal the diminishing role for anti–PD-1 monotherapy in the frontline setting, according to Ankit Mangla, MD.
RELATIVITY-048 Data Highlight Potential of Triplet ICI Regimen for Advanced Melanoma
The addition of ipilimumab (Yervoy) to nivolumab and relatlimab-rmbw (Opdualag) has generated high response rates and promising survival outcomes as a first-line treatment for patients with advanced melanoma in the phase 1/2 RELATIVITY-048 trial (NCT03459222), signifying the viability of triplet checkpoint blockade for this patient population, according to Ankit Mangla, MD. However, larger studies are needed to confirm the efficacy and safety of this approach for use in the frontline setting.
Combo immunotherapy produces distinct waves of cancer-fighting T cells with each dose
PHILADELPHIA – A new tool for monitoring immune health patterns over time has revealed how a pair of checkpoint inhibitor therapies works together to recruit new cancer-fighting T cells with every infusion. Findings from the use of the new tool, developed by researchers at the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center (ACC), were published today in Cancer Cell. The study challenges fundamental assumptions about how a common immunotherapy drug combination activates different types of T cells to defeat cancer and could help researchers more precisely measure immune response in future clinical trials.
Individualized neoantigen therapy could be ‘huge leap’ toward personalized medicine
Treatment induced sustained T-cell responses among patients with melanoma and non-small cell lung cancer.
Yale Research Highlights Unmet Needs for Patients With Melanoma Who Progress or Relapse After Immunotherapy Treatment
A retrospective cohort study by Yale Cancer Center researchers of nearly 200 patients with melanoma who died after receiving treatment with immunotherapy highlights a need to improve outcomes for patients after the treatment.
Adjuvant Pembrolizumab vs Placebo in Stage III Melanoma: Long-Term Health-Related Quality of Life
In an analysis from the phase III EORTC 1325-MG/KEYNOTE-054 trial reported in The Lancet Oncology, Bührer et al found that adjuvant pembrolizumab was not associated with significant differences in long-term health-related quality of life (HRQOL) compared with placebo in patients with stage III melanoma.
Treatment Practices in Metastatic Melanoma
Allison Betof Warner, MD, PhD, and the Oncology Brothers share clinical insights on treatment decisions for patients with metastatic melanoma.
Distinct Pattern in Protein Production Can P redict Severe Side Effects from Skin Cancer Treatment
An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy designed to treat the most deadly skin cancer, a new study shows.
TCR CDR3s and renalase-1 linked to increased melanoma survival
A new research paper titled “Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival" has been published in Oncotarget.
Cancer Vaccine for NSCLC and Melanoma Could Be Paradigm-Changing
The cancer vaccine, mRNA-4157, garnered immune responses of 30 weeks among some patients with melanoma and lung cancer, study results showed.
Free sunscreen offered at several popular Maine beaches as part of Harvard study
OLD ORCHARD BEACH, Maine — Approximately one person dies of melanoma every hour in the U.S., according to the American Cancer Society.
Individualized cancer therapy demonstrates safety and sustained immune responses
For decades, researchers have worked to develop therapies that can prime the immune system to recognize and attack proteins on the surface of tumor cells.
Neoadjuvant Therapy in Melanoma
Medical oncologists provide comprehensive insights on neoadjuvant therapy options for patients with melanoma.
Mapped: Melanoma cases in Virginia
Before you leave the house to enjoy Richmond’s sunny forecasts this week, lather on some sunscreen.
Hispanic Men With Melanoma Have Reduced Survival, Disease-Specific Disparities
Hispanic men with cutaneous melanoma receive melanoma diagnoses at an older age, show advanced-stage disease, present with melanoma of the trunk rather than lower extremities, and have reduced disease-specific survival when compared with Hispanic women with melanoma, according to study results published in Skin Health and Disease.
TCR CDR3s and renalase-1 linked to increased melanoma survival
BUFFALO, NY- August 8, 2024 – A new research paper was published in Oncotarget’s Volume 15 on August 5, 2024, entitled, “Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival.”
Link between UV and skin cancer
Excessive UV radiation damages DNA in skin cells producing genetic mutations that can lead to skin cancer.
Melanoma: predicting immunotherapy-induced side effects
Scientists at NYU Langone Health and its Perlmutter Cancer Center have revealed that an activity pattern in genes that build spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy.
Pattern in Protein Production May Be Predictive of Side Effects From Immunotherapy in Patients With Melanoma
An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases may predict the occurrence of severe side effects from immunotherapy in patients with melanoma, according to a recent study published by Monson et al in Clinical Cancer Research.
Gene signature predicts severe adverse events from ICI therapy for melanoma
The spleen tyrosine kinase pathway was upregulated in patients that had severe toxicities from immune checkpoint inhibitor therapy.
Study links renalase-1 and T-cell receptor interaction to increased melanoma survival
A new research paper was published in Oncotarget’s Volume 15 on August 5, 2024, entitled, “Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival."
ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma
Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.
Resected Melanoma: Subsequent Systemic Therapy After Recurrence on Adjuvant Nivolumab
In an analysis from the phase III CheckMate 238 trial reported in the Journal of Clinical Oncology, Jeffrey Weber, MD, PhD, and colleagues found that progression-free and overall survival were improved with subsequent systemic therapy following late vs early recurrence with adjuvant nivolumab in patients with resected stage IIIB–C or IV melanoma.
Toripalimab sNDA Under Review in China for Frontline Unresectable or Metastatic Melanoma
A sNDA seeking the approval of toripalimab for frontline use in patients with unresectable or metastatic melanoma is under review by the NMPA.
Two New Studies Show How Immunotherapies Collaborate to Boost T Cell Responses in Melanoma
Two studies published in the latest issue of the journal Cell by University of Pittsburgh researchers uncover how immunotherapies targeting the immune checkpoints PD1 and LAG3 work together to activate immune responses.
Dr Long on Unmet Needs in BRAF-Mutant Melanoma
Georgina V. Long, MBBS, PhD, FRACP, co-medical director, Melanoma Institute Australia (MIA), and chair, Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, The University of Sydney, discusses the remaining unmet needs for patients with BRAF-mutant melanoma and how data from the phase 3 NADINA trial (NCT04949113) could help address some of these needs.
Impact of PD-1 and PD-L1 Expression on Overall Survival in Patients With NSCLC and Melanoma
The conventional treatment paradigms for melanoma and non–small cell lung cancer (NSCLC) have historically centered around surgery, radiation, and chemotherapy.
New Studies Show How Immunotherapies Collaborate to Treat Melanoma
New studies have uncovered how immunotherapies targeting the immune checkpoints PD1 and LAG3 work in concert to active immune responses and may improve outcomes in patients with melanoma compared with monotherapies targeting only PD1.
Dr Tarhini on Hogh-Dose Bolus IL-2 With Ipilimumab Followed by Nivolumab in Melanoma
Ahmad Tarhini, MD, PhD, director, Cutaneous Clinical and Translational Research, leader, Neoadjuvant and Adjuvant Translational Science Program, senior member, Moffitt Cancer Center, Research Institute Departments of Cutaneous Oncology and Immunology; professor, Oncologic Sciences, University of South Florida Morsani College of Medicine; chair, Scientific Committee, Oncology Research Information Exchange Network (ORIEN); chair, ORIEN ImmunoOncology Research Subcommittee, discusses the use of high-dose bolus interleukin-2 (IL-2) with concurrent low-dose ipilimumab (Yervoy), followed sequentially by nivolumab (Opdivo), in patients with advanced melanoma.
15-year-old Virginia scientist created a soap that could treat skin cancer, named Time’s 2024 Kid of the Year
Time magazine and Time for Kids has chosen its 2024 Kid of the Year — and it’s Heman Bekele, a teenager who could change the way skin cancer is treated.
Innovative Melanoma Treatment Among NCInnovation’s $5.2 Million Research Funding Recipients
Michelle Bolas and Rukiyah T. Van Dross-Anderson, PhD, discuss the significance of NCInnovations’ funding and the clinical impact of Van Dross-Anderson’s research in patients with advanced melanoma.
Giant Melanocytic Nevi Portend More Aggressive Melanomas in Younger Patients
Melanomas that develop from giant pigmented nevi are diagnosed in younger patients more commonly than other melanomas; and while more these are more aggressive in patients younger than 10 years of age, they are mostly localized at the time of diagnosis, according to study results published in the Journal of the American Academy of Dermatology.
Do You Really Need to Wear Sunscreen?
You may have noticed a trend popping up on your social media feeds this summer: posts that claim you don’t need to wear sunscreen and that label certain kinds of sunscreen as toxic or question if sunscreen does more harm than good.
High Melanoma Self-Check Fail Rate Hikes Cancer Risk
Australians are unable to recognise malignant melanomas on their own skin, calling into question the effectiveness of national self-detection guidelines, according to new Southern Cross University research.
New Method Unlocks Treatment for Melanoma’s Brain Invasion
A study explored a new approach to treating melanoma that has spread to the meninges, the membranes surrounding the brain and spinal cord (leptomeningeal disease or LMD).
Researchers Urge Caution of Immunotherapy in Older Patients with Melanoma
Citing toxicities and lack of efficacy, some are calling for caution when treating older patients with melanoma with immune checkpoint inhibitors.
Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma
Paolo Ascierto, MD, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, discusses primary results from the phase 2 NEO-TIM trial which sought to determine the optimal sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with patients with high-risk melanoma.
Tumor-infiltrating lymphocyte therapy marks a milestone in cancer treatment, researchers say
The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy. In a new commentary published in Cancer Cell, Moffitt Cancer Center scientists provide a comprehensive overview of the therapy’s development and highlight its transformative potential.
Presurgical Targeted Therapy, Immunotherapy Show Responses in Melanoma
Researchers have found that among patients with certain melanoma, presurgical targeted therapy and immunotherapy can result in better pathologic response.
Some melanoma cancer cells may punch their way through the body
Imagine tiny fists punching their way through your body.
Study Takes a Closer Look at Eye Cancer’s High Rate of Metastasis
Uveal melanoma is a rare cancer type with an incidence of 7.6 per million adults in Australia and represents around 5% of all melanomas.
Live From Chicago: Bringing Sun Protection Awareness to Communities
Renata Block, MMS, PA-C, interviews dermatology clinicians and the Melanoma Research Foundation CEO at the Chicago SPF Fest.
New genetic clues about melanoma revealed through powerful imaging
Researchers use molecular imaging to uncover the genetic factors that drive this aggressive skin cancer
Why Does Melanoma Disproportionately Affect Men?
While no one can control their health completely, at this point it would be naive to think that the odds of getting cancer are completely left up to chance.
OBX-115: A Promising TIL Therapy for Melanoma
OBX-115 is a novel engineered tumor infiltrating lymphocyte (TIL) therapy designed to treat patients with checkpoint inhibitor-resistant metastatic melanoma.
Combination of Gene Expression Test and Antigen Status Offers Improved Prognostic Information in Uveal Melanoma
The addition of RNA expression of the cancer-testis antigen PRAME (preferentially expressed antigen in melanoma) to a 15-gene expression profile (15-GEP) offered significantly improved and more precise prognostic information over the 15-GEP alone.
New nanoparticles boost immune system in mice to fight melanoma and breast cancer
Vanderbilt researchers have developed a set of nanoparticles that stimulate the immune system in mice to fight cancer and may eventually do the same in humans.
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
A new research paper was published in Oncotarget entitled, “Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma."
Color blindness and differentiating between choroidal melanoma and choroidal nevus
A few studies have highlighted the differences between healthcare professionals with CVD and those with normal color vision.
TIL Therapy Plus IL-2 as Second-Line Treatment for Advanced Melanoma
Tumor-infiltrating lymphocyte (TIL) therapy in combination with high-dose interleukin-2 (IL-2) should be considered as a second-line treatment of choice for patients with advanced melanoma who have received anti-PD-(L)1 therapy, according to researchers.
BNT111 Plus Cemiplimab Generates Responses in Unresectable Stage III/IV Melanoma
BioNTech has announced positive topline findings from an ongoing phase 2 trial (NCT04526899) evaluating the investigational mRNA cancer immunotherapy BNT111 in combination with cemiplimab (Libtayo) for patients with unresectable stage III or IV melanoma who experienced disease progression following anti-PD-(L)1 therapy.
Sun exposure is driving rise in most melanoma cases
Doctors are diagnosing more people with melanoma.
Immunotherapy combination improves response in unresectable melanoma
An immunotherapy combination improved outcomes compared with historical control for certain patients with advanced melanoma, according to a topline data announcement.
BNT111/Cemiplimab Combo Significantly Improves ORR in Unresectable Melanoma
The safety profile of BNT111 plus cemiplimab was consistent with previous trials assessing BNT111 with anti–PD-L1 treatments.
Site-Specific Melanoma Trends May Be Related to Genetic Risk
WEDNESDAY, July 31, 2024 (HealthDay News) — Site-specific melanoma incidence trends may be partially related to genetic risk, according to a study published online July 19 in the British Journal of Dermatology.
Integrated 15-GEP and PRAME Classifier Shows Prognostic Accuracy in Uveal Melanoma
Integrating 15-GEP with PRAME expression status into a 4-group prognostic classification system showed prognostic accuracy in uveal melanoma.
Study provides novel insights into the molecular mechanisms of melanoma progression
Cong Peng et al., at Department of Dermatology, Xiangya Hospital, Central South University, China, conducted a study titled “NETO2 promotes melanoma progression via activation of the Ca²?/CaMKII signaling pathway" that investigates the role of Neuropilin and tolloid-like 2 (NETO2) in melanoma, a deadly form of skin cancer.
Melanoma In Situ of Smaller Size Has Low Recurrence With 5-mm Margin for Excision
Excision with 5-mm margins for melanoma in situ that is less than 10 mm in size on low-risk body sites is associated with a low recurrence rate, according to a study published in JAMA Dermatology.
Study uncovers the role of NETO2-mediated regulation in melanoma progression
Cong Peng and others at the Department of Dermatology, Xiangya Hospital, Central South University, China, conducted a study titled “NETO2 promotes melanoma progression via activation of the Ca2+/CaMKII signaling pathway," which investigated the role of Neuropilin and tolloid-like 2 (NETO2) in melanoma, a deadly form of skin cancer.
Treatment Algorithm for Stage IIB and Beyond Melanoma
Allison Betof Warner, MD, PhD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with stage IIB and beyond melanoma.
The ‘hidden’ Australian skin cancer problem that has researchers concerned
Melanoma is typically the most serious type of skin cancer diagnosed but new research has raised concerns about other high-risk forms of non-melanoma skin cancer.
Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annual Meeting (Abstract 9500) and published their findings in The New England Journal of Medicine.
Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics
Yu-Hwa Huang, Ph.D. and Charles Yoon, MD, of the Department of Medicine and Department of Surgery at Brigham and Women’s Hospital respectively, are co-lead authors of a paper titled “High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance," published in Communications Medicine. In this article, they discuss their findings.
Enhance early detection of melanoma with liquid lenses
Melanoma, a deadly form of skin cancer, poses a significant global health concern.
Check for signs of skin cancer
The sooner a skin cancer is identified and treated, the better your chance of avoiding surgery or, in the case of a serious melanoma or other skin cancer, potential disfigurement or even death.
SkylineDx Announces All Patients Enrolled in Landmark Study MERLIN_001, Advancing Melanoma Diagnostics
ROTTERDAM, Netherlands and SAN DIEGO, July 9, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, proudly announces the successful enrollment of the MERLIN_001 study.
Engineered TIL Cell Therapy Fast Tracked for Advanced Melanoma
The Food and Drug Administration (FDA) has granted Fast Track designation to OBX-115 for the treatment of metastatic, or locally advanced melanoma that is refractory to, or has relapsed after programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1)–based immune checkpoint inhibitors (ICI).
Tell Me, ChatGPT, Is This a Melanoma?
In September 2023, a new feature was added to ChatGPT (OpenAI) that allows the analysis of images, including those obtained through dermatoscopy.
New Standard in Melanoma May Save $1 Billion While Improving Lives
A new standard is poised to transform melanoma care in terms of both patient outcomes and economics. Results from the phase 3 NADINA trial (Abstract LBA2), presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that a six-week course of neoadjuvant immunotherapy was superior to two years of adjuvant immunotherapy in treating macroscopic, resectable stage III melanoma.
Bristol Myers Squibb’s Opdualag approved by SMC for advanced melanoma
Bristol Myers Squibb (BMS) has announced that its new immunotherapy combination, Opdualag (nivolumab-relatlimab), has been accepted by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for advanced melanoma.
First-of-its-kind clinical trial eliminates or shrinks melanoma tumors in 70% of patients
A clinical trial has shown that a new drug combination utilized before surgery completely eliminated or shrunk melanoma tumors in 70% of trial participants.
Skin cancer the focus of new pharma campaign
While the rates of many cancer types are projected to continue to decrease, melanoma remains a notable outlier. In fact, Merck Canada says the number of Canadians receiving a diagnosis of melanoma each year continues to rise, more than tripling in the past 30 years.
Dr. Farma Discusses Skin Cancer Prevention and Treatment
In an ACS news release, Metropolitan Philadelphia CoC State Chair Jeffrey M. Farma, MD, FACS, recently offered tips for preventing skin cancer and understanding options for treatment.
Daromun Shows Promising Results in Reducing Melanoma Recurrence and Metastasis
It is injected directly into the tumor, but its effectiveness has a broader range of action that also prevents the appearance of distant metastases.
Unmet Needs Persist for Patients with Melanoma
Melanoma was the topic of some of the most exciting abstracts at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting.
“Homemade Sunscreen Is Also Homemade Melanoma” — Nara Smith Blasted for DIY Sunblock
It’s no secret that TikTokers have uploaded some objectively stupid content to the platform — like people seemingly blindfolding themselves while driving for the Bird Box challenge.
High-Risk Melanoma: Inhibiting MEK and PD-L1 in Tandem
Cobimetinib and atezolizumab administered prior to surgery eliminated or shrunk tumors in 70% of patients with melanoma enrolled in the NeoACTIVATE trial. Results were published by Hieken et al in Nature Communications.
Neoadjuvant Immunotherapy Trial Sees High pCR Rates in Stage III Melanoma
A new study suggests a short course of immunotherapy before surgery may significantly improve outcomes in patients with high-risk melanoma.
Rosacea and melanoma strongly linked, big data says
Rosacea patients have more than five times the risk of developing a malignant melanoma and a greater risk of several other systemic conditions, according to researchers.
5-mm Margin May Be Enough for Excising Small Melanoma in Situ
Sun C, Lim A, De’Ambrosis B, et al. Recurrence Rate of Small Melanoma in Situ on Low-Risk Sites Excised With 5-mm Excisional Margin. JAMA Dermatol (2024).
Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma
Adjuvant nivolumab (Opdivo) in combination with ipilimumab (Yervoy) significantly improved 3-year distant metastasis–free survival (DMFS) rates compared with historical controls in patients with high-risk uveal melanoma, according to findings from the phase 2 HCRN MEL17-309 trial (NCT03528408) presented at the 2024 ASCO Annual Meeting.
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the first article of a 2-part series.
New approach to improve targeted skin cancer therapies
(Vienna, 16 July 2024) Targeted therapies are a powerful weapon against skin cancer, but their side effects can severely impact a patient’s quality of life.
The Role of Neoadjuvant Immunotherapy Advances in Resectable Stage III Melanoma
NADINA trial results support a new standard of care for these patients.
Exciting Progress for Difficult-to-Treat Advanced Melanoma — What to Know About Biologic Drug Brenetafusp
An exciting biologic drug called brenetafusp is being studied, and showing real promise, in treating advanced cutaneous melanoma.
RELATIVITY-048: Triplet Immunotherapy Shows Activity in Untreated Advanced Melanoma
As a first-line treatment of advanced melanoma, the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab produced high response rates and promising progression-free and overall survival in the nonrandomized phase I/II RELATIVITY-048 trial, as reported by Paolo Antonio Ascierto, MD, of the Istituto Nazionale dei Tumori IRCCS in Naples, Italy, at the 2024 ASCO Annual Meeting.
Melanoma Brain Metastases: New Study Offers Insight for More Effective Cancer Treatment
For those living with advanced melanoma, brain metastases— malignant growths that occur when cancer cells travel to the brain—are particularly challenging to treat.
Dr Khushalani on Fixed-Dose Treatment Regimens in Advanced Melanoma
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the benefits and limitations of fixed-dose treatment regimens, such as the combination of fianlimab (formerly REGN 3767) and cemiplimab-rwlc (Libtayo) that is under investigation in the phase 3 HARMONY HEAD TO HEAD trial (NCT06246916) in patients with unresectable or metastatic melanoma.
How to protect your skin from sun damage and cancer
A previous version of this article incorrectly said that skin cancer is diagnosed in 20 percent of Americans each year. It should have said that skin cancer is diagnosed in 20 percent of Americans in their lifetime. The article has been corrected.
Does Dabrafenib-Trametinib Improve Overall Survival in Melanoma?
In patients with resected stage III melanoma, adjuvant therapy with dabrafenib plus trametinib reduces the risk for death by 20% compared with placebo, though the overall survival benefit does not reach statistical significance.
Iovance submits EU marketing authorization for lifileucel for advanced melanoma
Iovance Biotherapeutics has submitted a marketing authorization application to the European Medicines Agency for lifileucel to treat advanced melanoma, the company announced in a press release.
High fail rate for melanoma self-checks increasing cancer risk, new study finds
Australians are unable to recognize malignant melanomas on their own skin, calling into question the effectiveness of national self-detection guidelines, according to new Southern Cross University research.
New Cancer Vaccine Shows Promise in Melanoma
A new cancer vaccine targeting melanoma, currently the subject of a phase 2 trial, has shown “promising” results, as one researcher tells CURE®.
Advanced Melanoma: Efficacy of Monoclonal Antibody Doublet
In a phase I trial reported in the Journal of Clinical Oncology, Omid Hamid, MD, and colleagues found that the combination of the human lymphocyte activation gene-3 (LAG-3)-targeting monoclonal antibody fianlimab plus the PD-1–targeting monoclonal antibody cemiplimab-rwlc was active in patients with advanced melanoma.
Call for urgent melanoma screening
Australia must implement a national melanoma screening program like those in place for bowel and breast cancer say Queensland health researchers.
Patients failing at melanoma self-checks: Study
Well-meaning patients are putting their lives at risk, with a new study finding most people are unable to self-diagnose skin cancer on their own bodies.
Faecal transplants can treat some cancers — but probably won’t ever be widely used
In February 2021, a pair of remarkable clinical trials was published1,2. Each one involved people with melanoma. Some participants had been successfully treated using drugs called immune checkpoint inhibitors, which help the body to destroy cancer cells. The others had failed to respond to the treatment.
EMA validates Philogen and Sun Pharma’s MAA for melanoma
The European Medicines Agency (EMA) has validated Philogen and Sun Pharmaceutical’s marketing authorisation application (MAA) for Nidlegy, a treatment for melanoma.
Rosacea, melanoma linked in white patients
Patients with rosacea have an increased risk for malignant melanoma, joint problems, metabolic disease and visual disturbances, according to a study.
A ‘World-Class Leader’ in Melanoma Oncology Plans to Help Build a Pinnacle Program in the Rockies
Sapna Patel, MD, a widely renowned melanoma oncologist and clinical investigator, has joined the University of Colorado Cancer Center and the CU Department of Medicine, with a goal of helping to build a “pinnacle of skin cancer treatment” in the Rocky Mountains.
Rural Patients With Melanoma Fare Worse Than Urban Dwellers
Among people diagnosed with cutaneous melanoma in the United States, those who live in rural areas have significantly lower rates of survival than those who live in urban areas, results from an analysis of data from the National Cancer Institute showed.
The Froedtert & MCW Cancer Network announces novel cell therapy treatment for advanced melanoma
Milwaukee — Today, the Froedtert & MCW Cancer Network announced it will begin to offer new treatment to patients with advanced melanoma. Lifileucel, created by Iovance, is the first cell therapy treatment to be FDA approved for the deadliest form of skin cancer.
Dual immunotherapy treatment before surgery in melanoma patients
Neoadjuvant immunotherapy given for stage III melanoma, followed by adjuvant therapy only if there is not a deep response to treatment, promises better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone.
Triplet Immunotherapy Shows Promise in Early-Phase Trial of Untreated Advanced Melanoma
The triplet combination of nivolumab, relatlimab, and ipilimumab offered promising response rates and survival outcomes in patients with untreated advanced melanoma, according to preliminary data from the nonrandomized phase 1/2 RELATIVITY-048 trial (Abstract 9504). Although the results require confirmation in larger randomized trials, the 4-year overall survival (OS) rate seen with the triplet regimen compares favorably with other nivolumab-based combinations in this setting.
Long-Term Follow-Up Still Shows Tafinlar/Mekinist Benefit in Melanoma
Eight-year follow-up showed that Tafinlar plus Mekinist continued to improve outcomes for patients with stage 3 melanoma.
Targeted induction before immunotherapy shows limited benefit in advanced melanoma
CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.
Neoadjuvant immunotherapy ‘the new standard’ for resectable stage III melanoma
CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.
Intralesional Therapy for Melanoma Effective, May Have Systemic Activity
CHICAGO — Preoperative intralesional treatment with a dual antibody-cytokine fusion significantly improved relapse-free survival (RFS) in locally advanced melanoma versus surgery alone, a randomized trial showed.
Practice-Changing Results From the NADINA Trial
Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)
Neoadjuvant Nivolumab/Ipilimumab New Standard of Care for Stage III Melanoma
Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) followed by therapeutic lymph node dissection (TLND) and response-driven adjuvant therapy reduced the risk of progression, recurrence, or death by 68% compared with TLND and adjuvant nivolumab alone for patients with macroscopic stage III node-positive melanoma, according to findings from the phase 3 NADINA study presented at the 2024 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine.
Nivolumab Combo Improves EFS in Stage III Melanoma
Phase 3 findings show the benefit of immunotherapy before surgery in those with macroscopic stage III node-positive melanoma.
An mRNA Melanoma Vaccine Shows Promise
Moderna says the same mRNA technology that fueled its COVID-19 vaccine is proving effective in fighting melanoma.
In Stage III Melanoma, Immunotherapy Combo Before Surgery Leads to Improved Survival, Less Therapy
The idea that patients could get better responses with shorter courses of therapy runs counter to the current standard of care in melanoma.
World-first vaccine for melanoma cuts risk of death in half, trial finds
A world-first personalised vaccine for melanoma vaccine has been found to reduce the risk of cancer reoccurrence or death by 49 per cent over three years.
The ‘cancer treatment revolution’ targetting melanoma
In Australia one person is diagnosed with the deadly skin cancer, melanoma, every 30 minutes. But there is hope.
Side Effects of Mektovi: What You Need to Know
Mektovi (binimetinib) is a prescription drug that’s used to treat certain types of cancer. Mektovi can cause side effects that range from mild to serious. Examples include nausea, diarrhea, and vomiting.
From immunotherapy to mRNA vaccines – the latest science on melanoma treatment explained
More than 16,000 Australians will be diagnosed with melanoma each year. Most of these will be caught early, and can be cured by surgery.
UC San Diego Health first in region to provide novel therapy for melanoma
UC San Diego Health is the first hospital system in the region to offer a new immunotherapy treatment for metastatic melanoma. The personalized cellular therapy derived from tumor infiltrating lymphocytes (TIL), is the first solid tumor therapy on the market approved by the U.S. Food and Drug Administration (FDA).
New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings
The oncolytic immunotherapy RP1 in combination with nivolumab (Opdivo) displayed activity in patients with melanoma who failed prior anti–PD-1 treatment, according to updated findings from the phase 2 IGNYTE trial (NCT03767348).
TikTok influencers claim sunscreen is harmful. Here’s why that’s wrong, and dangerous
Summertime is coming to Florida, which means fun in the sun, cool drinks, blue skies, and, possibly, skin cancer.
Researchers discover new therapeutic target for the treatment of melanoma resistant to targeted therapies
An international research team led by scientists from the University of Liège has discovered an interesting new therapeutic target for the treatment of melanoma resistant to targeted therapies.
Uveal Melanoma Immunogenomic Score Shows Predictive Potential
Investigators examined 100 metastases and developed a Uveal Melanoma Immunogenomic Score to predict which patients will respond to immunotherapy.
Pembrolizumab/Vibostolimab Coformulation for Melanoma to be Discontinued
The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.
Not all treatments created equal: Identifying barriers to immunotherapy for melanoma
Immunotherapy is an effective yet very expensive treatment for melanoma.
How can general practitioners better detect melanoma?
Thanks to a new skin cancer screening technology developed by Latvian researchers, clinicians across the EU may soon have access to a portable device that can detect melanoma without a biopsy.
Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma
The phase 3 KeyVibe-010 trial (NCT05665595) evaluating the combination of adjuvant vibostolimab (MK-7684A) and pembrolizumab (Keytruda) vs pembrolizumab alone in patients with resected high-risk stage IIB, IIC, III, and IV melanoma has been discontinued.
Disparities in Melanoma Outcomes Among Black Patients
Investigators may have uncovered sex-based disparities in the detection and survival of melanoma in Black patients, according to a recent study published by Steadman et al in the Journal of Surgical Oncology.
Skin Cancer Awareness Month: Sun Safety and Tackling Diagnosis
For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.
Asian American and Pacific Islander Patients Face Increased Odds of Melanoma Treatment Delay
Researchers say addressing socioeconomic differences may be the key to addressing this disparity.
Atkins Considers Comorbidities That Limit Use of IO Doublet in Advanced Melanoma
PARTICIPANT LIST Raymond Lobins, DO | David Potter, MD | Mark Karwal, MD | Shahid Waheed, MD | Somasekhara R. Bandi, MD | Christiane Zoghbi, MD | Hilary Ufearo, MBBS
Biomarker could improve prediction of response to immunotherapy in melanoma
If melanoma spreads, there are various therapies that can be used. However, there is still insufficient research into who responds to which therapy and whether resistance may develop over time.
Patient Preference Plays Limited Role in Selection of Therapy for Melanoma
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.
Clinical trials pilot program a gamechanger for regional patients
If it weren’t for clinical trials, Gippsland’s Steve Wadey says he wouldn’t be alive today.
Skin Cancer Awareness Month: TILs Offer New Hope in Advanced Melanoma
Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.
Adjuvant Vaccine Combo May Prolong Survival in Melanoma
A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.
QUIZ: Dermoscopy and Melanoma Detection
Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month.
QUIZ RECAP: Dermoscopy and Melanoma Detection
Earlier this week, we shared our third Skin Cancer Awareness Month quiz. Review the answers and your responses below.
Reviewing the Skin Cancer Pipeline: A Look at the Last 10 Years
In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.
Inherited genes play a larger role in melanoma risk than previously believed
When it comes to skin cancer, most people think of warnings about sunburn and tanning beds.
An estimated 100K melanomas will be diagnosed in 2024
It’s estimated that more than 100,000 melanomas will be diagnosed this year.
More Clinicians are Needed in the Fight Against Skin Cancer
Andrew Baker, MBA, MPAS, PA-C, discusses his role in skin cancer detection and advice for PAs interested in skin surgeries and Mohs closures.
Cancer Vaccines Approach New Horizons in Melanoma and Other Solid Tumors
The personalized cancer vaccine research paradigm is expanding, with particular advancements occurring in patients with high-risk melanoma, in whom vaccines have been shown to induce and strengthen responses to immunotherapy, according to Patrick Ott, MD, PhD.
Genetics Play a Larger Role in Melanoma Than Previously Thought
A person’s genetics play a more prominent role in melanoma than previously believed, according to a study published in the Journal of the American Academy of Dermatology.
Exploring TIL Therapy for Recurrent Melanoma Treatment
TIL (tumor-infiltrating lymphocyte) therapy is a promising new approach for treating advanced melanoma. It leverages the power of a patient’s own immune system to combat cancer cells.
AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices
An artificial intelligence-based smartphone app used by primary care physicians showed high diagnostic accuracy in detecting cutaneous melanoma.
CNIO researchers explore new ways of attacking melanoma, an increasingly frequent cancer in which prevention is crucial
On the left melanoma cells (in green) can be seen surviving in the presence of cytotoxic lymphocytes (red), when they express one of these immunosuppressive proteins.
The Aussie truck saving lives one skin check at a time
A team that travels to schools on a truck offering free skin cancer checks saved a young boy who was unknowingly living with melanoma on his ear.
Melanoma skin cancer cases rising in UK
A cancer charity is warning people to do more to protect themselves from the sun as the number of melanoma skin-cancer cases in the UK continues to rise.
Looking Ahead for Melanoma Treatment
While checkpoint inhibitors are a mainstay in the field of advanced melanoma treatment, novel and reimagined therapies offer new hope for this challenging disease state.
PCSK9 May Serve as a Potential Therapeutic Target for Skin Melanoma
A new study found proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with an increased cutaneous melanoma risk.
How Derm Deserts Are Harming Our Skin
Two years ago, in the fall of 2022, the American Dermatological Association (ADA) effectively declared war on health disparities in skincare, citing a concept many of us had not heard: medical deserts.
TIL Therapy: A New Melanoma Treatment 30 Years in the Making
Almost two-thirds of patients diagnosed with metastatic melanoma are expected to die within five years, but a newly approved treatment may help some patients live longer.
Age-related skin changes may contribute to melanoma metastases among older adults
Age-related changes to the skin’s elasticity may drive higher rates of metastatic skin cancer among older individuals, according to study results.
New study shows vitamin C boosts DNA damage and cell death in melanoma cells
A recent study shows that there may be a more effective way to treat melanoma by using ascorbate (vitamin C) to increase DNA damage in cancer cells, leading to their death, according to co-corresponding author of the study Marcus Cooke, professor and chair in the Department of Molecular Biosciences.
SkylineDx’s Merlin Assay stratifies Stage I/II cutaneous melanoma beyond SLNB for recurrence
ROTTERDAM, Netherlands, and SAN DIEGO, May 30, 2024 /PRNewswire/ — SkylineDx announces the presentation of groundbreaking data at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.
Pembrolizumab/Vibostolimab Coformulation for Melanoma to be Discontinued
The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.
Not all treatments created equal: Identifying barriers to immunotherapy for melanoma
Immunotherapy is an effective yet very expensive treatment for melanoma.
How can general practitioners better detect melanoma?
Thanks to a new skin cancer screening technology developed by Latvian researchers, clinicians across the EU may soon have access to a portable device that can detect melanoma without a biopsy.
Merck Discontinues KeyVibe-010 Trial of Vibostolimab/Pembrolizumab in Resected High-Risk Melanoma
The phase 3 KeyVibe-010 trial (NCT05665595) evaluating the combination of adjuvant vibostolimab (MK-7684A) and pembrolizumab (Keytruda) vs pembrolizumab alone in patients with resected high-risk stage IIB, IIC, III, and IV melanoma has been discontinued.
Disparities in Melanoma Outcomes Among Black Patients
Investigators may have uncovered sex-based disparities in the detection and survival of melanoma in Black patients, according to a recent study published by Steadman et al in the Journal of Surgical Oncology.
Asian American and Pacific Islander Patients Face Increased Odds of Melanoma Treatment Delay
Researchers say addressing socioeconomic differences may be the key to addressing this disparity.
Skin Cancer Awareness Month: Sun Safety and Tackling Diagnosis
For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.
Atkins Considers Comorbidities That Limit Use of IO Doublet in Advanced Melanoma
During a Case-Based Roundtable® event, Michael B. Atkins, MD, discussed the choice of therapy for a 78-year-old patient with metastatic melanoma with participants.
Biomarker could improve prediction of response to immunotherapy in melanoma
If melanoma spreads, there are various therapies that can be used. However, there is still insufficient research into who responds to which therapy and whether resistance may develop over time.
Patient Preference Plays Limited Role in Selection of Therapy for Melanoma
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.
Clinical trials pilot program a gamechanger for regional patients
If it weren’t for clinical trials, Gippsland’s Steve Wadey says he wouldn’t be alive today.
Skin Cancer Awareness Month: TILs Offer New Hope in Advanced Melanoma
Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.
Adjuvant Vaccine Combo May Prolong Survival in Melanoma
A multipeptide vaccine combination approach may extend survival in stage IIB to IV melanoma.
QUIZ: Dermoscopy and Melanoma Detection
Click here to read more and answer our quiz questions in recognition of Skin Cancer Awareness Month.
QUIZ RECAP: Dermoscopy and Melanoma Detection
Earlier this week, we shared our third Skin Cancer Awareness Month quiz. Review the answers and your responses below.
Reviewing the Skin Cancer Pipeline: A Look at the Last 10 Years
In recognition of Skin Cancer Awareness Month, Dermatology Times is reviewing research and strides in skin cancer treatment over the last decade.
Inherited genes play a larger role in melanoma risk than previously believed
When it comes to skin cancer, most people think of warnings about sunburn and tanning beds. Thoughts of “cancer genes" or inherited risks are reserved for diseases like breast cancer or colon cancer. A new study challenges this status quo by showing that genetics play a larger role in melanoma risk than recognized.
More Clinicians are Needed in the Fight Against Skin Cancer
Andrew Baker, MBA, MPAS, PA-C, discusses his role in skin cancer detection and advice for PAs interested in skin surgeries and Mohs closures.
An estimated 100K melanomas will be diagnosed in 2024
It’s estimated that more than 100,000 melanomas will be diagnosed this year.
Cancer Vaccines Approach New Horizons in Melanoma and Other Solid Tumors
The personalized cancer vaccine research paradigm is expanding, with particular advancements occurring in patients with high-risk melanoma, in whom vaccines have been shown to induce and strengthen responses to immunotherapy, according to Patrick Ott, MD, PhD.
Genetics Play a Larger Role in Melanoma Than Previously Thought
A person’s genetics play a more prominent role in melanoma than previously believed, according to a study published in the Journal of the American Academy of Dermatology.
Exploring TIL Therapy for Recurrent Melanoma Treatment
TIL (tumor-infiltrating lymphocyte) therapy is a promising new approach for treating advanced melanoma. It leverages the power of a patient’s own immune system to combat cancer cells.
AI Support Tool Demonstrates Detection Utility for Melanoma at Primary Care Practices
An artificial intelligence-based smartphone app used by primary care physicians showed high diagnostic accuracy in detecting cutaneous melanoma.
CNIO researchers explore new ways of attacking melanoma, an increasingly frequent cancer in which prevention is crucial
By investigating the origin and evolution of melanoma, several groups at the Spanish National Cancer Research Center (CNIO), who are international leaders in the field, have come up with promising strategies.
The Aussie truck saving lives one skin check at a time
A team that travels to schools on a truck offering free skin cancer checks saved a young boy who was unknowingly living with melanoma on his ear.
Melanoma skin cancer cases rising in UK
A cancer charity is warning people to do more to protect themselves from the sun as the number of melanoma skin-cancer cases in the UK continues to rise.
Looking Ahead for Melanoma Treatment
While checkpoint inhibitors are a mainstay in the field of advanced melanoma treatment, novel and reimagined therapies offer new hope for this challenging disease state. These therapies include using older agents like interluekin-2 (IL-2) or tumor-infiltrating lymphocytes (TILs) and modifying them to make their activity more potent against melanoma. Additionally, oncolytic vaccines administered into the tumor or systemically can help to sensitize the immune system and improve the response to checkpoint inhibitors.
PCSK9 May Serve as a Potential Therapeutic Target for Skin Melanoma
A new study found a greater PCSK9 is associated with a greater cutaneous melanoma risk.
How Derm Deserts Are Harming Our Skin
Two years ago, in the fall of 2022, the American Dermatological Association (ADA) effectively declared war on health disparities in skincare, citing a concept many of us had not heard: medical deserts.
Age-related skin changes may contribute to melanoma metastases among older adults
Age-related changes to the skin’s elasticity may drive higher rates of metastatic skin cancer among older individuals, according to study results.
New study shows vitamin C boosts DNA damage and cell death in melanoma cells
A recent study shows that there may be a more effective way to treat melanoma by using ascorbate (vitamin C) to increase DNA damage in cancer cells, leading to their death, according to co-corresponding author of the study Marcus Cooke, professor and chair in the Department of Molecular Biosciences.
SkylineDx’s Merlin Assay stratifies Stage I/II cutaneous melanoma beyond SLNB for recurrence
ROTTERDAM, Netherlands, and SAN DIEGO, May 30, 2024 /PRNewswire/ — SkylineDx announces the presentation of groundbreaking data at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.
Dr Olson on the Potential Benefit of Lifileucel in Relapsed/Refractory Metastatic Melanoma
Daniel Olson, MD, assistant professor, medicine, the University of Chicago Medical Center, UChicago Medicine, discusses the benefit associated with lifileucel (Amtagvi) in patients with unresectable or metastatic melanoma, highlighting patients likely to derive the most benefit from this treatment approach.
National boost for melanoma care and research
The Paula Fox Melanoma and Cancer Centre – a partnership between Monash University, The Alfred and Minderoo Foundation – is set to revolutionise care for Victorian patients.
Evidence Lacking on Best Surveillance Strategies for Melanoma
Results of a systematic review provide insights that may help guide surveillance in patients with melanoma, but the results also suggest more data are needed to identify optimal surveillance strategies, according to researchers. The researchers shared their findings in Surgical Oncology.
Dr Patel on the Evolving Use of Neoadjuvant PD-1 Inhibitors in CSCC
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences; director, Cutaneous Oncology Program, GW Cancer Center, discusses the evolving use of PD-1 inhibitors for patients with cutaneous squamous cell carcinoma (CSCC) in the neoadjuvant and adjuvant setting.
Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients
Desai emphasized that most dermatologists would rather biopsy a potential melanoma than miss one that could become deadly.
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
OBX-115 With Acetazolamide Induces Safe and Durable Antitumor Responses in Advanced Melanoma
Intravenous infusion with OBX-115, an IL-2–free, regulatable, engineered tumor-infiltrating lymphocyte (TIL) cell therapy was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma, according to data from a first-in-human, single-center, phase 1 study (NCT05470283) presented at the 2024 AACR Annual Meeting.
British man tests first personalised melanoma vaccine
An important trial of the world’s first “personalised" mRNA vaccine against the deadliest form of skin cancer – melanoma – is now under way in the UK.
Music teacher’s ‘bump on the head’ turned out to be high-risk melanoma
A music teacher whose “bump on the head” turned out to be potentially deadly melanoma is taking part in a groundbreaking clinical trial.
Exploration of Melanoma Incidence, Mortality Rates Urges Further Research
A retrospective analysis out of Denmark could not find a causal relationship to explain trends in melanoma incidence and mortality rates, demonstrating the need for more research in this area.
Toxicities Hinder Potential Efficacy of Ceritinib/Trametinib in Pretreated Advanced Melanoma
Although dual suppression of the mTOR and MAPK pathways could be a viable therapy avenue for patients with pretreated advanced melanoma, overcoming overlapping toxicities when combining these types of therapies will be paramount, according to Zeynep Eroglu, MD.
Personalized Melanoma Vaccine Could Be a ‘Game Changer’ by Teaching the Body to Fight Cancer Cells
A global trial has begun for the world’s first personalized vaccine for melanoma—the deadliest form of skin cancer, which affects about 132,000 people per year. If successful, the therapy will prevent melanoma from returning in patients who have already been treated.
Dermatologists warn of dangers of unregulated cosmetic laser industry
Dermatologists are warning of the dangers of the unregulated cosmetic laser industry after a woman’s melanoma was mistaken for a sunspot.
Cutaneous Malignant Melanoma Global Incidence Increased, Mortality Decreased
Despite an increasing prevalence of cutaneous malignant melanoma (CMM) worldwide, CMM-associated mortality has decreased in recent years, according to study results published in Melanoma Research.
Survivors of Early-Stage Melanoma Have High Rates of Fear of Recurrence, Study Finds
The study aimed to improve the understanding of lived experiences and the fear of recurrence among survivors of localized, stage 0 to IIA cutaneous melanoma.
Fact vs. Fiction: Debunking Common Misconceptions about Skin Cancer, Sun Safety
ATLANTA, April 30, 2024 – In the United States, more than 5 million cases of skin cancers are diagnosed each year. Despite its prevalence, there are still a number of misconceptions surrounding the disease.
Dr Eroglu on Addressing Unmet Needs in Mutant Melanoma
Zeynep Eroglu, MD, medical oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center; assistant professor, Department of Oncologic Sciences, the University of South Florida Morsani College of Medicine, discusses unmet needs that currently exist for patients with mutant melanoma, highlighting a phase 1/2 trial (NCT03501368) that evaluated ceritinib (Zykadia) alone and in combination with trametinib (Mekinist) for these patients.
Immunogenomics Demonstrate Predictive Capability to Immunotherapy Resistance in Uveal Melanoma
Immunogenomic factors were found to be predictive of resistance to immunotherapy and to tumor susceptibility to the therapeutic class in patients with metastatic uveal melanoma, according to findings from a study published in Nature Communications.
Personalised mRNA vaccines: a revolutionary new approach in melanoma treatment
A personalised mRNA vaccine to treat melanoma has now reached late-stage trials in the UK. This is just the latest step in improving the cure rate of cancer.
Adjuvant Multipeptide Vaccine Combination Prolongs Survival in Melanoma
A multipeptide vaccine combination approach with 12MP plus 6MHP vs 12MP plus tet extended overall survival in patients with stage IIB to IV melanoma.
Encorafenib Alone or With Binimetinib Provides Long-Term Benefits in Melanoma
Encorafenib, given with or without binimetinib, provides long-term benefits for patients with BRAF V600E/K-mutant advanced melanoma, according to results from the phase 3 COLUMBUS trial published in the European Journal of Cancer.
Recognizing Melanoma and Skin Cancer Awareness Month
Our May issue of Dermatology Times spotlights melanoma/skin cancer awareness and more.
Alpha-9 Oncology doses first subject in phase 1 study for new melanoma diagnostic agent
Alpha-9 Oncology has dosed the first participant in its study evaluating Ga-A9-3202 for the imaging of melanoma.
Years after his death, late scientist’s work could yield new cancer treatments
Some of the final work of a late University of Virginia School of Medicine scientist has opened the door for life-saving new treatments for solid cancer tumors, including breast cancer, lung cancer and melanoma.
Melanoma cases rise despite unchanging mortality rate
From 1999 to 2019, the incidence of invasive melanoma cases increased by 2.5-fold.
Model for Predicting Outcomes After Sentinel Lymph Node Biopsy in Melanoma
In a study reported in The Lancet Oncology, Stassen et al developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma.
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Akoya Biosciences, NeraCare Partner to Develop Melanoma Tests
NEW YORK – Spatial biology company Akoya Biosciences and German prognostic test developer NeraCare said Thursday that they have inked an exclusive agreement to develop assays for skin cancer.
Scientists discover how deadly skin cancer evades the human immune system
An international study led by Dr. Li Qi-Jing from the Agency for Science, Technology and Research (A*STAR) has revealed a mechanism by which melanoma, the most aggressive form of skin cancer, evades the immune system.
FOCUS Trial of HEPZATO KIT Shows Efficacy in Metastatic Uveal Melanoma
A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.
Melanoma in darker skin tones: Race and sex play a role, Mayo study finds
ROCHESTER, Minn. — Melanoma, an aggressive form of skin cancer that accounts for 75% of all skin-cancer-related deaths, is often detected later in people with darker skin complexions — and the consequences can be devastating, a Mayo Clinic study reveals.
Symptoms of melanoma other than a mole
Melanoma is the most dangerous type of skin cancer. It begins in the cells that produce melanin (called melanocytes) and control your skin pigment.
Melanoma Monday: From Early Detection to Cutting-Edge Treatments
Melanoma, the deadliest form of skin cancer, is on the rise. But there’s a silver lining as this increase might be partly due to earlier detection.
Tumor Diameter of Melanoma Demonstrates Statistically Significant Correlation With Survival
Researchers found that the diameter of cutaneous melanoma demonstrated a weak positive correlation with tumor thickness.
Illuminating a Potential Culprit in Melanoma Treatment Resistance
Researchers may have uncovered the mechanisms behind the development of targeted therapy resistance in melanoma, according to a recent study published by Aya Moreno et al in Cell Reports.
Melanoma tumours produce altBRAFs by genomic deletions
Researchers at the Centre for Genomic Regulation (CRG) have discovered one of the mechanisms through which melanoma drug resistance occurs.
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Dr Hamid on the Use of Lifileucel in Advanced Melanoma
Omid Hamid, MD, director, Melanoma Program, Cedars-Sinai Medical Center, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, Phase I Immuno-Oncology Program, The Angeles Clinic and Research Institute, discusses the use of lifileucel (Amtagvi) in the treatment of patients with advanced melanoma.
Pitt researchers uncover mechanisms behind uveal melanoma resistance
New research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells outside the body before reinfusing them, can successfully treat this rare and aggressive cancer.
Factors Driving Use of Adjuvant Therapy for Stage III Melanoma
A survey of oncologists and review of patient data revealed factors driving decisions about adjuvant therapy for patients with stage III melanoma.
New insights could unlock immunotherapy for rare, deadly eye cancer
New research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient’s T cells outside the body before reinfusing them, can successfully treat this rare and aggressive cancer.
Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma
Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma, according to a recent study published by Leonard-Murali et al in Nature Communications. The findings demonstrated the potential to improve personalized therapies and avoid unnecessary treatments in metastatic uveal melanoma.
Shape-shifting cancer cell discovery reveals two potential drug targets against skin cancer
Scientists have discovered how skin cancer cells shapeshift based on their environment – enabling them to spread through the body and cause a metastatic cancer.
Dr Olson on Toxicities Associated With Lifileucel and IL-2 in Melanoma
Daniel Olson, MD, assistant professor, medicine, the University of Chicago Medical Center, UChicago Medicine, discusses toxicities associated with lifileucel (Amtagvi) and interleukin-2 (IL-2)in patients with unresectable or metastatic melanoma.
Dr Kirkwood on the Evolving Treatment of Resected Melanoma
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh, discusses the significance of the FDA approval of adjuvant nivolumab (Opdivo) for patients with resected stage IIB or IIC melanoma.
TIL Therapy Promising in Uveal Melanoma, Tool Predicts Responders
A type of therapy that involves “liberating” T cells from a suppressive tumor environment showed promise in the treatment of patients with uveal melanoma.
ESMO: Breakthroughs in Melanoma Treatment Regimens
Hello. I’m Dr Jeffrey Weber. I’m a medical oncologist at the Laura and Isaac Perlmutter Cancer Center in New York City at NYU Langone Health.
Dr Hamid on Addressing Unmet Needs in Relapsed Melanoma With Lifileucel
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute, discusses how the tumor-infiltrating lymphocyte (TIL) lifileucel (Amtagvi) may address historical unmet needs in relapsed melanoma.
SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma
Uveal Melanoma Immunogenomic Score Shows Predictive Potential
Investigators have developed a Uveal Melanoma Immunogenomic Score (UMIS) to predict which patients with metastatic uveal melanoma will respond to immunotherapy, according to findings published in Nature Communications.
Dr Olson on the Potential Benefit of Lifileucel in Relapsed/Refractory Metastatic Melanoma
Daniel Olson, MD, assistant professor, medicine, the University of Chicago Medical Center, UChicago Medicine, discusses the benefit associated with lifileucel (Amtagvi) in patients with unresectable or metastatic melanoma, highlighting patients likely to derive the most benefit from this treatment approach.
Australian of the Year Richard Scolyer ‘blown away’ by success of radical new brain cancer treatment
World-first clinical trials of a groundbreaking treatment for aggressive brain tumours are likely to begin soon following “fantastic" results in the high-profile case of Australian of the Year, Professor Richard Scolyer.
Men With Melanoma Who Receive Enhanced Vaccine Experience Improvements in Overall Survival
It is unclear why the vaccines were less effective in women, but researchers note that the findings can be important when determining immune therapy outcomes in patients with melanoma.
Meta-Analysis: Rate of Malignancy Low in Pediatric Longitudinal Melanonychia
Despite a high frequency of atypical features, longitudinal melanonychia (LM) in children is associated with an exceedingly low rate of malignancy.
Melanoma Survivors Should ‘Talk Through’ Fear of Recurrence
Melanoma survivors may have an increased risk of recurrence, which may heighten fear and worry, but “it’s OK and normal to be worried,” a doctor said.
Selecting Observation Vs Immunotherapy in Advanced Melanoma
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.
Model for Predicting Recurrence-Free and Melanoma-Specific Survival After SLNB in Melanoma
In a study reported in The Lancet Oncology, Stassen et al developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma.
New Vaccine Improves Survival Among Patients with Melanoma
A vaccine developer discusses a cancer vaccine that has been shown to potentially boost long-term overall postsurgical survival.
Untreated obstructive sleep apnea raises risk for poor prognosis in melanoma
The risk for death, melanoma recurrence or metastasis was high among patients with this cancer and untreated obstructive sleep apnea vs. no sleep apnea.
Immunohistochemistry May Improve Melanoma Diagnosis
A retrospective analysis of Medicare data revealed that between 2000 and 2017, immunohistochemistry (IHC) claims associated with melanoma diagnoses grew from 11% to 51%.
Epitope editing shields healthy blood cells from immunotherapies
Monoclonal antibodies and immunotherapy are potent cancer treatments, but preventing treatment resistance to these therapies is challenging.
A melanoma subtype emerges from the shadows
Unprotected exposure to ultraviolet (UV) radiation from the sun or other sources is a key risk factor for cutaneous melanoma, the most aggressive form of skin cancer. Having fair skin also increases the risk. The countries with the highest incidence of melanoma, including Australia, New Zealand, and Denmark, are largely composed of populations of European descent (1).
Nivo-Ipi More Effective, More Toxic Than Anti-PD-1 Monotherapy in High-Risk Melanoma
Neoadjuvant treatment with nivolumab and ipilimumab (nivo-ipi) is more effective but more toxic than anti-PD1 monotherapy for patients with high-risk, resectable melanoma, according to research published in JAMA Oncology.
Yes-Associated Protein May Hold Prognostic Value in Cutaneous Melanoma
A retrospective study analyzing tissue assays from patients with cutaneous melanoma demonstrated the promise of yes-associated protein (YAP) as a predictive biomarker for melanoma prognosis.
Independent European data on CP-GEP model in Stratifying Melanoma Patients for Long Term Survival
ROTTERDAM, Netherlands and SAN DIEGO, April 5, 2024 /PRNewswire/ — SkylineDx is pleased to announce two forthcoming scientific publications at the European Association for Dermato-Oncology congress, April 4-6, 2024.
Science Fiction Becomes Fact: Neoantigen Therapy in Melanoma
This transcript has been edited for clarity.
Childhood obesity not linked to adult skin cancer risk, study says
A recent Scientific Reports study investigates whether genetically predicted childhood adiposity influences the risk of developing skin cancer in adulthood.
Dr Migden on RP1 in Advanced Cutaneous Malignancies After Solid Organ Transplant
Michael R. Migden, MD, dermatologist, professor, Department of Dermatology, Division of Internal Medicine and Head and Neck Surgery, Division of Surgery, and program director, ACGME Fellowship:Micrographic Surgery and Dermatologic Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy data from the phase 1b/2 ARTACUS trial (NCT04349436) evaluating the oncolytic immunotherapy RP1 in patients with advanced non-melanoma cutaneous malignancies who underwent prior solid organ transplant.
Sunbeds ‘should have graphic cancer warning signs like cigarettes’
Tanning salons should have graphic warning signs similar to those found on cigarette packets in order to warn customers about the dangers of using sunbeds, a support group has said.
Better Melanoma Follow-Up Adherence May Reduce Melanoma-Specific Mortality
In the setting of primary cutaneous melanoma, better adherence to annual dermatology follow-up visits was associated with reduced melanoma-specific mortality, according to study findings published in the Journal of the American Academy of Dermatology.
AI-Based Smartphone App Proves Reliable in Diagnosis of Melanoma
A prospective study evaluating the efficacy of an artificial intelligence (AI)–based clinical support system further demonstrated the reliability of AI or machine learning as a diagnostic tool in skin cancer.
CP-GEP Model Successful in Stratifying Node-Negative Patients into Risk Groups for Melanoma Disease Progression
According to 2 studies, this model has demonstrated the potential to assist in developing treatment and monitoring plans for early-stage melanomas.
Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti-PD1 Therapy in High-Risk Resectable Melanoma
Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Doctors Weigh Patient Goals Instead of ‘Dictating’ Melanoma Treatment
An expert explained the importance of patient choice in treatment decisions for high-risk, resectable melanoma, based on their own treatment goals.
SCIB1 Vaccine May Synergize With Nivo-Ipi Against Melanoma
An investigational vaccine, SCIB1, has demonstrated activity when used in combination with nivolumab and ipilimumab in patients with advanced melanoma, according to research presented at the AACR Annual Meeting 2024.
Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment
Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.
Reflectance Confocal Microscopy Enhances Detection Sensitivity for Flat Amelanotic/Hypomelanotic Melanoma Differential Diagnosis
Diagnostic accuracy of lesions was enhanced with combined dermoscopy and reflectance confocal microscopy, according to one study.
Melanomas resist drugs by ‘breaking’ genes
Melanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to alleviate the health burden of the disease.
Examining the Link Between Melanoma Thickness and Patient Age at Diagnosis
Researchers observed significant stepwise increases in median Breslow lesion thickness with increasing age at diagnosis of invasive melanoma in White patients in the United States and general population in Australia, according to a letter to the editor published in the Journal of Investigative Dermatology.
Genomic deletions explain why some types of melanoma resist targeted therapies
Melanoma is the deadliest form of skin cancer. With global incidence rates rising, new, more effective treatments are necessary to alleviate the health burden of the disease. Important advances in recent years include doctors using genetic tests to look for specific mutations they can target for more personalized, effective treatment.
End The Trend – Campaign Hub
The Australian Government and Cancer Council have partnered to encourage young Australians aged 18-30 to #EndTheTrend of skin cancer and adopt SunSmart behaviours.
Federated Learning Models Show Potential in Melanoma-Nevus Classification, but Improvements Needed
A multicentric, single-arm diagnostic study created a decentralized federated learning model for the classification of invasive melanomas and nevi, showcasing comparable results to centralized data models.
Melanoma: over 100 thousand years of life lost in Europe in 1 year
“Don’t think about it” is the worst advice you can follow for preventing melanoma. A suspected mole, in fact, should never be ignored or neglected for too long.
TILT-123/TIL Combo Appears Safe and Feasible in Metastatic Melanoma
When given alone or with tumor infiltrating lymphocyte therapy, TILT-123 given intravenously or intratumorally is safe and feasible for patients with advanced metastatic melanoma.
Many survivors of localized melanoma fear recurrence despite favorable prognosis
Despite the high cure rate of localized cutaneous melanoma, many patients who undergo successful surgical resection experience severe anxiety and fear about the possibility of recurrence, according to findings published in JAMA Dermatology.
Lifileucel Shows Long-Term Efficacy in Melanoma
In patients with advanced melanoma, lifileucel showed durable efficacy and a 4-year overall survival rate of 21.9%, according to long-term findings from the phase 2 C-144-01 trial.
Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy
China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
China’s National Medical Products Administration (NMPA) has approved tunlametinib (HL-085) for the treatment of patients with advanced melanoma harboring NRAS mutations who were previously treated with anti–PD-1/PD-L1 therapy.
Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma
As reported in the Journal of Clinical Oncology by Jason J. Luke, MD, FACP, and colleagues, the final prespecified analysis of distant metastasis–free survival in the phase III KEYNOTE-716 trial showed continued benefit with adjuvant pembrolizumab vs placebo in patients with resected stage IIB or IIC melanoma.
First China, then the world: new MEK blocker wins melanoma nod
Shanghai-based KeChow Pharma has secured approval in its home country for tunlametinib, a MEK blocker which was discovered and developed by the firm in-house.
AI-based mobile app can diagnose melanoma with very high precision
A mobile app that uses artificial intelligence, AI, to analyze images of suspected skin lesions can diagnose melanoma with very high precision.
Gene specific alternative polyadenylation can reduce tumor growth
Cells regulate RNA and protein abundance through a multi-layered process. Excitingly, peeling back one layer has revealed additional layers below, highlighting the complex nature of this process.
Lifileucel Approval Signals a Turning Point in Melanoma Therapy
Lifileucel’s FDA approval marks a breakthrough in melanoma treatment, offering hope with promising antitumor activity. While its potential extends to various solid tumors, challenges persist.
BMS Health Hub: cultivating conversations about melanoma
Michelle Norton, skin cancer clinical nurse specialist at Velindre Cancer Centre, Cardiff, shares her perspectives on the burden of an advanced melanoma diagnosis, and how this digital Health Hub helps her to support her patients with advanced melanoma from diagnosis through to treatment.
Lifileucel for Unresectable or Metastatic Melanoma
On February 16, 2024, lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, was granted accelerated approval for adults with unresectable or metastatic melanoma previously treated with a PD-1–blocking antibody, and if BRAF V600 mutation–positive, a BRAF inhibitor with or without a MEK inhibitor.
Adjuvant Nivolumab in Stage IIB/C Melanoma
On October 13, 2023, nivolumab was approved for adjuvant treatment of completely resected stage IIB/C melanoma in patients aged 12 years and older.
She is awarded the Sjöberg Prize for laying the foundations of a cancer vaccine
Catherine J. Wu, of the Dana-Farber Cancer Institute in Boston, USA, is a pioneer in research that may result in the development of personalised vaccines to treat cancer.
Managing Immune-Related Toxicities Key to Immunotherapy for Skin Cancer
Incidence of melanoma and keratinocyte (nonmelanoma) skin cancers, such as squamous cell and basal cell carcinomas (SCC and BCC, respectively), continues to increase, but mortality rates are stable or declining because of an explosion of treatment options, including numerous immunotherapy regimens, according to an oral presentation at the 2024 Oncology Nurse Advisor Summit.
AI-based app can help physicians find skin melanoma
A mobile app that uses artificial intelligence, AI, to analyse images of suspected skin lesions can diagnose melanoma with very high precision. This is demonstrated by a national study involving researchers from the University of Gothenburg. For the study, the app has been tested in clinical practice at primary care centers.
Perlmutter Cancer Center Clinical Trial Tests Personalized mRNA Vaccine for Treating Metastatic Melanoma
Vaccines developed using mRNA technology helped turn the tide during the COVID-19 pandemic. Now, researchers at NYU Langone Health’s Perlmutter Cancer Center and other cancer centers around the world are looking at using mRNA vaccines to personalize cancer treatment.
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Why a new law is preventing some teens from achieving a pre-summer glow
WAUSAU, Wis. (WSAW) – According to the Skin Cancer Foundation, melanoma is the second most common form of cancer for teens 15 – 19 years old.
Regulatory T Cell Involvement in Melanoma Prognosis and Treatment Strategy
According to a recent study published in Environmental Toxicology, regulatory T cells (Tregs) play a crucial role in immune suppression within the melanoma microenvironment.
Older adults, men at increased risk for second primary melanoma diagnosis
Patients aged 40 years and younger saw longer interval times between melanoma incidences vs. patients aged 50 to 59 years and 80 years or older.
Enhanced melanoma vaccine offers improved survival for men (IMAGE)
Craig L. Slingluff Jr., MD, and his team at UVA Cancer Center have developed a second-generation melanoma vaccine to treat the dangerous skin cancer.
AI-Powered Detection System for Skin Cancers Receives FDA Approval
The first real-time, non-invasive skin cancer evaluation system, which can detect basal cell carcinoma, melanoma, and squamous cell carcinoma, has been granted clearance by the FDA, according to a press release from DermaSensor Inc.
AI Accurately Predicts Skin Cancer Risk Based on 2D Facial Images
An artificial intelligence (AI) mode was more accurate in assessing patient risks for skin cancer through the analysis of 2D facial images compared with more traditional risk-factor screening.
Skin Cancer Overdiagnosis in White Americans Is Increasing, Study Says
An ecological study revealed increasing rates of skin cancer overdiagnosis in white Americans.
Cheaper medicines for advanced melanoma and multiple sclerosis
From 1 February 2024, Australians with advanced melanoma and relapsing-remitting multiple sclerosis (MS) will have access to new and updated medicines under the Pharmaceutical Benefits Scheme (PBS).
Review: Neoadjuvant Dual ICIs Offer Better Response Than Anti-PD1 Monotherapy in High-Risk Resectable Melanoma
An alternative dose of ipilimumab and nivolumab had less toxicity than a conventional dose, the results show.
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
On February 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, for adult patients with unresectable or metastatic melanoma who were previously treated with a PD-1 blocking antibody, or, if they have BRAF V600 mutation–positive disease, a BRAF inhibitor with or without a MEK inhibitor.
C-144-01 Trial
Early FDG PET/CT Scanning May Predict Treatment Response in Melanoma
Imaging after 1 week of treatment with pembrolizumab may help identify treatment responses in patients with metastatic melanoma.
Delayed Melanoma Diagnoses from COVID-19 Lockdown Cost £6 Billion in Europe
A new study has shown that delays in diagnosis of melanoma in Europe due to COVID-19 lockdowns may have contributed to the loss of more than 100,000 life-years and costs that exceed £6 billion, mostly related to loss of productivity.
Addition of Lifileucel to Advanced Melanoma Arsenal Marks Milestone for TIL Therapy in Solid Tumor Management
As the first cellular and tumor infiltrating lymphocyte (TIL) therapy product to be approved by the FDA for patients with solid tumors, lifileucel (Amtagvi) could usher in a paradigm shift in advanced melanoma management, thereby paving the way for several other TIL products to gain approval, according to Daniel Olson, MD.
Experience Shapes Use of Dual Immunotherapy in Advanced Melanoma
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed what patient factors and other considerations affect the choice of immunotherapy for patients with advanced BRAF-negative melanoma. This is the first of 2 articles based on this event.
Tackling Melanoma with Precision: The Quest for a Biomarker
Each year, the Cancer Center Amsterdam (CCA) Foundation champions cutting-edge cancer research by funding promising proposals from CCA researchers. This ‘seed-funding’ empowers CCA scientists to pursue innovative research directions in support of our goal to cure cancer.
Stage II and III Cutaneous Melanoma Associated With Lower Life Expectancy
Patients with stage II or III cutaneous melanoma had significantly decreased life expectancy (LE) compared to people in the general population, according to study results published in the Journal of the American Academy of Dermatology.
Groundbreaking Study Unveils Heightened Second Melanoma Risk in Older Men Post-First Diagnosis
Imagine finding out that your battle with melanoma, a formidable foe, might not be over with just one victory.
‘A tan is not worth dying for’; Jenny shares her melanoma journey
Geelong’s Jenny Thulborn, 60, first discovered she had melanoma 30 years ago after the birth of her second child. Now cancer-free, she will participate in the Melanoma Institute Australia’s Geelong Melanoma March on March 3. She speaks with Jena Carr about her journey through many health scares and surviving stage four melanoma.
New RMIT, CDU study finds cannabis has ‘deadly’ effect on melanomas in-vitro in laboratory
As Leigh Raaschou sits in his home detailing decades of paying the price of the sun, there isn’t a glimmer of despair.
Health experts the hot tip for sun safety advice
Queensland has the highest rate of melanoma in the world – so it’s important to heed the sun safety advice of health experts and slip, slop, slap and slide.
TIL Therapy for Advanced Melanoma Requires Nursing, Pharmacy Collaboration
An oncology nurse and pharmacist discuss the multidisciplinary approach to administering TIL therapy in patients with advanced melanoma.
Identifying a CAR T-cell therapy target for melanoma
A transmembrane glycoprotein known as tyrosinase-related protein 1 (TYRP1) has been identified as a potential target for a CAR T-cell therapy that treats melanoma.
UV1 Vaccination Plus Nivolumab/Ipilimumab Falls Short in Metastatic Melanoma
The addition of the universal cancer vaccine UV1 to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did not improve progression-free survival (PFS) compared with nivolumab plus ipilimumab alone in the first-line treatment of patients with unresectable or metastatic melanoma, failing to meet the primary end point of the phase 2 INITIUM trial (NCT04382664).
AMERICAN ACADEMY OF DERMATOLOGY: MILITARY MEMBERS MORE AT RISK FOR MELANOMA
Board-certified dermatologist discusses occupational risks of skin cancer for those who serve
Health care professionals enthusiastic about approval of first cell therapy for melanoma
HCPs online celebrated the approval of lifileucel for advanced melanoma.
After stage 4 melanoma diagnosis, treatment, William Shatner shares new outlook on life
Actor William Shatner shared his melanoma story with attendees of the American Academy of Dermatology Annual Meeting.
Age-Related Changes in Skin May Contribute to Melanoma Metastases
Age-related changes that cause the skin to stiffen and become less elastic may also contribute to higher rates of metastatic skin cancer in older people, according to research by investigators from the Johns Hopkins Kimmel Cancer Center.
Smoking Status at Time of Melanoma Diagnosis May Impact Survival
Being a current smoker at the time of a clinical stage I and II primary cutaneous melanoma diagnosis was associated with an increased risk for melanoma-associated death compared with never smoking and former smoking, according to study results published in JAMA Network Open.
Aussies ‘traumatised’ by Cancer Council’s ‘terrifying’ melanoma ad from the 2000s: ‘I still know every word’
Australians are reminiscing on a ‘haunting’ TV commercial from the 2000s and 2010s that left them ‘scarred for life’.
Lifileucel Data Encourage Expansion to Solid Tumor Setting
It is a promising time for cellular therapy, and combinations with gene modification or other systemic or local therapies bode well for solid tumor development of this TIL therapy platform.
Cancer Prevalence in Europe as of 2020
In a study reported in The Lancet Oncology, De Angelis et al estimated the numbers of patients alive after a cancer diagnosis in Europe as of 2020.
AHN Launches Cutting-Edge Melanoma and Skin Cancer Center
In an interview with Targeted Oncology, Howard D. Edington, MD, discussed Allegheny Health Network’s recently unveiled Melanoma and Skin Cancer Center and its new technology.
Dosing and Regimen Changes Promote Tolerability in Advanced Melanoma
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed dosing considerations and toxicity when choosing combination treatment for patients with melanoma. This is the second of 2 articles based on this event.
More Than 100K New Cutaneous Melanoma Diagnoses Expected in 2024
SAN DIEGO — According to data from the American Cancer Society (ACS), cutaneous melanoma was the fifth most common cancer in 2023, with an estimated 97,610 new cases and 7,990 deaths, following cancer of the colorectal area, lung and bronchus, prostate, and breast.
Smoking Tied to Increased Mortality From Early-Stage Melanoma
Patients with clinically localized primary cutaneous melanoma who smoked cigarettes at the time of diagnosis had an increased risk of melanoma-associated mortality, a cohort study showed.
Exploring the Emergence of Genomic Testing in Dermatology
A team of dermatology physician assistants recently reviewed the current and future potential of genomic testing in the realm of dermatology.
Immune networks in tumors found to prime responses to personalized immunotherapy
Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T-cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL)
A surprising look at the mechanics of metastasis
February 7, 2024—Scientists at Harvard T.H. Chan School of Public Health are peering deep inside lymph nodes to learn more about how cancer cells spread—and whether we may someday be able to halt metastasis through dietary modifications.
Smoking status associated with melanoma survival
Patients with melanoma who smoke had an increased risk for melanoma-associated death.
Dr Weber on the Background of the KEYNOTE-942 Trial in High-Risk Melanoma
Jeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.
New study reveals mechanism of cell death in melanoma cells by cannabis extract
A cannabis extract has shown positive results in slowing down melanoma cell growth and increasing cell death rates, a new in-vitro study finds.
Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis
Javid Moslehi, MD, presents Case 2, highlighting a 63-year-old female patient with metastatic melanoma on dual immunotherapy, illustrating treatment-related myocarditis and emphasizing key aspects of immunotherapy-induced cardiac toxicities.
Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy
Javid Moslehi, MD, shares expert perspectives on the diagnosis and management of immunotherapy-related myocarditis.
Lipson Considers Tolerability When Selecting Immunotherapy for Metastatic Melanoma
During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed tolerability factors that could influence the choice of frontline immunotherapy regimen for a patient with metastatic melanoma.
Androgen receptor signaling found to upregulate gene driving melanoma severity in men
In a recent study published by Nature Communications, researchers uncovered a previously unknown method by which androgen-activated androgen receptors (ARs) increase fucosyltransferase 4 (FUT4) expression, which promotes melanoma invasiveness by interfering with adherens junctions (AJs).
PRAME Shows Promise as a Treatment Avenue in Melanoma, Other Solid Tumors
Preferentially expressed antigen in melanoma has emerged as a target for treatment development in multiple solid tumors.
Smoking and Its Impact on Early-Stage Melanoma Survival: A Closer Look
A recent study published in JAMA Network Open has unveiled a critical connection between smoking and the mortality rates associated with early-stage melanoma.
Quest Diagnostics Debuts MelaNodal Predict™ Test, Personalizing Melanoma Risk Prediction to Help Patients Forgo Invasive Surgery
SECAUCUS, N.J., and SAN DIEGO, Feb. 13, 2024 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, today announced the launch of MelaNodal Predict™, a highly advanced predictive gene expression test to help personalize treatment decisions for patients with melanoma, the deadliest form of skin cancer and one of the most common cancers in the United States.
Clinical Data Lacking on Black Patients With Melanoma
A single-institution, retrospective cohort study evaluates knowledge gaps in clinical data on Black patients with melanoma.
MIA Calculator for Predicting Recurrence-Free and Overall Survival in Stage II Melanoma
In a study reported in the Journal of Clinical Oncology, Varey et al developed the Melanoma Institute Australia (MIA) calculator for predicting recurrence-free and overall survival in stage II melanoma and found that it outperformed modeling based on American Joint Committee on Cancer (AJCC)-8th edition melanoma staging.
Long-Term CheckMate 238 Data Support Adjuvant Nivolumab Vs Ipilimumab in Resected Melanoma
Adjuvant nivolumab (Opdivo) continued to significantly improve relapse-free survival (RFS) over ipilimumab (Yervoy) in patients with resected stage III or IV melanoma, according to 7-year minimum follow-up efficacy data from the phase 3 CheckMate 238 study (NCT02388906) presented at the 2023 ESMO Congress.
New Test Could Predict Immunotherapy Responders for Broader Range of Cancers than Current Tools
A newly identified genetic marker could potentially predict which patients are likely to respond to immunotherapy in cancer types that have lacked such tools until now, according to a study published in Cancer Immunology Research, a journal of the American Association for Cancer Research.
Advanced melanoma survival rates improve significantly from 2013 to 2019, Dutch study finds
In a recent study published in EClinicalMedicine, a group of researchers assessed the change in overall survival (OS) among advanced melanoma patients diagnosed between 2013 and 2021.
Risks of Melanoma, Other Skin Cancers Are Higher in Patients Treated With Biologics for Psoriasis
It is important to study the safety of targeted therapies in populations at increased risk of skin cancer, according to the researchers.
Dr Nathan on the Significance of Tebentafusp in HLA-A*02:01+ Uveal Melanoma
Paul D. Nathan, MBBS, PhD, FRCP, discusses the clinical significance of updated data on tebentafusp in metastatic uveal melanoma.
New Melanoma Metastasis Risk Prediction Tool Debuts
The test may help patients with melanoma safely avoid a sentinel lymph node biopsy.
Experts Give an Overview of the Latest Melanoma Therapies
Dr. Inderjit Mehmi and Dr. Omid Hamid from the Angeles Clinic, explain how therapies like targeted therapies, immunotherapy and T-cell therapies are improving outcomes for patients with advanced melanoma.
Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma
According to results from a retrospective cohort study, antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse progression-free survival (PFS) and overall survival (OS) results among patients with treatment-naïve cutaneous or mucosal melanoma when compared with antibiotic exposure after initiation of immune checkpoint blockade.
Cancer Vaccine Could Go ‘Above and Beyond Standard of Care’ For Patients
Moderna and Merck have initiated V940-001, a phase 3 study evaluating vaccine mRNA-4157 and anti-PD-1 therapy Keytruda as postsurgical treatment for stage 2B to 4 melanoma.
FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma
Today, the U.S. Food and Drug Administration approved Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor).
FDA Approves Lifileucel for Unresectable or Metastatic Melanoma
Adjuvant checkpoint inhibitor therapy is the standard of care for resectable melanoma. Although many patients derive lasting benefit from the treatment, a substantial number experience disease recurrence.
Forward Outlook and Clinical Insights in Melanoma Treatment
A group of oncology experts provide forward-looking perspectives and clinical insights in the treatment of melanoma.
Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.
Skin cancer is no joke: I’m one of the lucky ones but the threat of malignant melanoma still impacts my life
The Duchess of York, Sarah Ferguson, has been diagnosed with malignant melanoma, just six months after treatment for breast cancer. She had several moles removed during breast reconstruction surgery, with one of them being identified as cancerous.
Study reveals surprising power of CD4+ T cells against melanoma
Researchers have revealed unprecedented insights into CD4+ T cells, a type of immune cell, which show promise for immunotherapies against melanoma, the most severe form of skin cancer
Sarah Ferguson diagnosed with malignant melanoma – here are the latest treatments for this increasingly common skin cancer
News that Sarah Ferguson, the Duchess of York, has recently been diagnosed with malignant melanoma highlights the dangers of this increasingly common skin cancer.
Melanoma Overdiagnosis Rising Among White Patients
Almost 90% of white men and 85% of white women who received a diagnosis of melanoma in 2018 were likely overdiagnosed, according to a new study.
Data From ESMO 2023 Further Define Treatment Paradigm in Advanced Melanoma
Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.
Melanoma Overdiagnoses May Be Rising Among White U.S. Patients
Over 50% of all melanoma diagnoses among White patients in the United States may in fact be overdiagnoses, according to a recent study published by Adamson et al in BMJ Evidence-Based Medicine.
‘Shocking’ results reveal imaging can detect early response to immunotherapy for melanoma
FDG PET/CT imaging detected metabolic changes in patients with advanced melanoma beginning immunotherapy in the first week.
“Helper” T-cells pack more of a punch against tumors than first thought
CD4+ T-cells, primarily considered to play a supportive role in the anti-tumor immune response, have been seen to actively kill cancer cells in a mouse model of melanoma.
Personalized mRNA vaccine boosts melanoma immunotherapy
Adjuvant checkpoint inhibitor therapy is the standard of care for resectable melanoma. Although many patients derive lasting benefit from the treatment, a substantial number experience disease recurrence.
Melanoma specialists and Australians of the Year warn nation’s tanning culture is ‘killing us’
The 2024 Australians of the Year have warned the nation’s tanning culture is “killing us", but that hasn’t stopped people hitting the beach on a scorching Australia Day.
Your Cancer Answers: Should I be concerned about using a tanning bed?
On Jan. 1, 2012, California was the first state in the nation to ban use of UV indoor tanning beds for minors under 18.
Duchess’s diagnosis prompts skin cancer searches
Visits to the NHS melanoma skin cancer information page soared after the Duchess of York announced she’d been diagnosed with malignant melanoma.
Melanoma treatment pioneers joint Australians of the Year
Pioneers in melanoma treatment, professors Georgina Long and Richard Scolyer, are the joint 2024 Australians of the Year.
Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy
A panel of oncology experts explores the intricate balance between maintaining quality of life and managing toxicity in adjuvant immunotherapy for melanoma.
Breaking Australia’s suntanning obsession
As shocking new statistics show the continued popularity of tanning among young people and their belief that getting skin cancer is unlikely, a ground-breaking sun safe campaign is ramping up to change the attitudes and behaviours of 18–30-year-old Australians.
Sunsmart steps up prevention efforts
With UV levels now consistently at very high and extreme levels during summer, SunSmart Victoria is ramping up its “Don’t Let Cancer In” skin cancer prevention campaign as new data shows melanoma diagnoses could increase by 24 per cent over the next decade.
Cutaneous melanoma diagnosis may impact total life expectancy
Patients with stage II or III cutaneous melanoma lost a total of 2,209 and 1,902 life-years, respectively.
A Step Toward Overcoming a Melanoma Drug Resistance Pathway
Researchers have identified an epigenetic pathway involved in resistance to mitogen-activated protein kinase inhibitors, pointing the way to better patient treatment for resistant melanomas.
Imaging just one week after starting treatment can predict melanoma response to immunotherapy
While the standard timing for imaging patients’ tumors after immunotherapy is three months, researchers found that imaging patients with melanoma after just one week of treatment illuminated metabolic changes in their tumors that corresponded with a response to the treatment and longer survival, according to new research from the Perelman School of Medicine
Report Sheds Light on Critical Pathway Responsible for Treatment Resistance in Melanoma
Researchers may have uncovered a novel epigenetic pathway involved in the development of treatment resistance in melanoma and a chemical reagent that may be effective in resensitizing treatment-resistant tumors to targeted therapies, according to a recent study published by Wu et al in The Journal of Clinical Investigation.
Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management
Afreen Shariff, MD, MBBS, examines the surveillance and management of immunotherapy-induced adrenal insufficiency in the context of melanoma, underscoring the importance of maintaining a heightened awareness for early detection.
Immunotherapy-Related Diabetes in Melanoma: A Management Perspective
Afreen Shariff, MD, MBBS, discusses managing immunotherapy-related diabetes in melanoma, emphasizing the critical need to detect sudden changes in blood sugar levels and advocating for a multidisciplinary approach.
Number of Skin Cancer Cases Rising Rapidly
The number of skin cancer cases has doubled in two decades, and dermatologists expect it to rise even further. Melanoma, known to most people, accounts for only 10% of this figure.
Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL
A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.
How UV radiation damages skin, and how sunscreen protects against cancer and wrinkles
As the last weeks of summer melt into autumn, you might be tempted to leave sunscreen out of your morning skincare routine.
Sunscreen shouldn’t just be for holiday use. Here’s how much experts say to use each day
It’s estimated more than 18,000 people were diagnosed with melanoma — the deadliest form of sun cancer — in Australia last year.
Young Australians love tanning. What will it take to change their minds?
From Slip, Slop, Slap to “no hat, no play", today’s teenagers and young adults grew up with sun safety messages in their schools, homes, and TV and radio ads.
Rare Immune Cell May Predict Immunotherapy Response in Melanoma
Vd1-gd T cells, a rare type of immune cell, have been found to potentially predict how likely it is that certain patients with advanced skin cancer will be responsive to treatment via immunotherapy, according to recently published research.
DermTech’s cancer test has 99% accuracy in ruling out melanoma
The California-based DermTech has announced positive results from its Trust 2 study,tevaluating its system for ruling out melanoma showing a negative predictive value (NPV) of 99.7%.
‘We cannot tolerate this’: Rising costs stopping Aussies from crucial melanoma checks
Neil Breen expresses frustration over the high fees charged by specialists for skin checks, which can deter people from getting potentially life-saving screenings.
SkylineDx Announces Grant of European Patent and Advances in Melanoma Diagnosis and Treatment
ROTTERDAM, Netherlands and SAN DIEGO, Jan. 9, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on the research and development of molecular diagnostics, is excited to announce that the European Patent Office (EPO) has granted European Patent No. 3827101, marking a groundbreaking advancement in the field of cancer diagnostics and personalized treatment.
Researchers characterize the tumor suppressor activity of the PTEN protein in melanoma
Cutaneous melanoma is considered the deadliest form of skin cancer because it’s aggressive and tends to spread quickly through the body.
What’s the Plan for Patients With Melanoma After Surgery?
“When we talk about recurrence of melanoma, we actually worry more about what we cannot see, what’s on the inside,” Dr. Justine V. Cohen of the Dana-Farber Cancer Institute told CURE®.
Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma
Bristol Myers Squibb’s (BMS) Opdualag (nivolumab-relatlimab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line treatment of advanced melanoma in patients aged 12 years and older.
Immunotherapy Initiation at the End of Life for Patients With Metastatic Cancers
In an analysis reported in JAMA Oncology, Kerekes et al found that initiation of immunotherapy at the end of life has increased over time in U.S. patients with metastatic cancers.
Dr Possik on the Importance of Diversity and Equity in Melanoma Research
Patricia A. Possik, PhD, assistant investigator, Division of Cellular Biology, Brazilian National Cancer Institute, Rio de Janeiro, Brazil, discusses the importance of efforts to improve diversity, equity, and inclusion in melanoma research, including how a more diverse research landscape can influence the efficacy and relevance of treatment approaches in acral lentiginous melanoma.
3D scanner leaves no melanoma undetected
NICE Approves Nivolumab and Relatlimab Combination for Advanced Melanoma Treatment
The National Institute for Health and Care Excellence (NICE) has made a significant stride in the management of advanced melanoma by approving the drug combination of nivolumab and relatlimab as a first-line treatment.
AIM at Melanoma Celebrating 20 Year Anniversary
RICHMOND, Calif., January 11, 2024 (Newswire.com) – Twenty years ago, the AIM at Melanoma Foundation was established by a determined woman with a relentless drive to find the cure for melanoma while improving the lives of those it affects.
Collarium sun beds claiming to improve skin are increasing melanoma risk, skin cancer experts say
Queensland Health is investigating the legality of collarium tanning beds popping up in the state’s south east, despite sun beds being banned nationally from commercial operations since 2016.
DermTech’s 2-GEP Assay Succeeds at Guiding Biopsy Decision-Making for Ambiguous Skin Lesions of All Skin Phototypes
The promising results were presented in a poster at the 2024 Winter Clinical Hawaii Dermatology Conference in Honolulu, Hawaii.
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference – Hawaii®
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data across its dermatologic portfolio of commercially available and pipeline gene expression profile (GEP) tests at the 2024 Winter Clinical Dermatology Conference – Hawaii, being held Jan. 12-17 in Honolulu, Hawaii.
Communication Between Patients, Doctors Crucial After Melanoma Surgery
Patients with melanoma play a vital role in their own post-surgical care, as one expert explained to CURE®.
Rate of End-of-Life Immunotherapy Is on the Rise in Advanced Melanoma, NSCLC, RCC
The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time, according to findings from a cohort study led by investigators at the Yale School of Medicine.
ctDNA Patterns May Predict Outcomes Achieved With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma
The addition of a personalized mRNA vaccine to standard-of-care (SOC) pembrolizumab (Keytruda) improved survival outcomes vs pembrolizumab alone in resected high-risk melanoma, and monitoring ctDNA patterns over time can provide valuable insights into the degree of benefit patients can expect to achieve from the approach, according to Jeffrey S. Weber, MD, PhD.
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma.
ECOG-ACRIN Cancer Research Group melanoma research team led by Michael Atkins, MD, receives the 2023 Paper of the Year distinction from the Journal of Clinical Oncology
A team of melanoma researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is honored with the 2023 Paper of the Year distinction by the Journal of Clinical Oncology.
FDA Clears Non-Invasive AI Device for Skin Cancer Detection
The DermaSensor device demonstrates a high rate of sensitivity in the detection of more than 200 types of skin cancers in a clinical study.
Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma
This is a video synopsis/summary of an OncLive Insights® involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.
The secret life of CD4+ T cells: from helpers to melanoma fighters
In the study led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and published in Science Immunology, the researchers found that CD4+ T cells, traditionally called ‘helper T cells’ for their role in aiding the activation of other immune cells, are remarkably effective in controlling melanoma.
Doctors slam Kim Kardashian’s tanning bed boast after sister’s melanoma diagnosis
They say trends recycle, but the early aughts tanning bed craze is one we probably shouldn’t relive.
Cancer vaccine with minimal side effects nearing Phase 3 clinical trials
Dr. Thomas Wagner, founder of the biotech company Orbis Health Solutions and cancer researcher, has made it his life’s mission to find a way to treat cancer without the dreaded side effects that, for some, can become worse than the cancer itself or may even lead to an earlier death.
Melanoma Treatment to be listed on PBS
A new treatment for advanced melanoma is set to be made available on the pharmaceutical benefits scheme.
Sarah Ferguson diagnosed with malignant melanoma – here are the latest treatments for this increasingly common skin cancer
News that Sarah Ferguson, the Duchess of York, has recently been diagnosed with malignant melanoma highlights the dangers of this increasingly common skin cancer.
Moderna, Merck vaccine with Keytruda cuts risk of deadly skin cancer returning in half, data says
Moderna and Merck’s experimental cancer vaccine, when used in combination with Merck’s blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer by half after roughly three years, according to midstage trial data released Thursday.
Wistar scientists enhance cell-based therapy to destroy solid tumors
PHILADELPHIA—(Dec. 13, 2023)—Wistar researchers successfully tested a simple intervention that could unlock greater anti-tumor power in therapies that use T cells — an approach known as “cell-based therapy,” which uses specially designed T cells to fight cancer. Led by Dr. Hildegund C.J. Ertl — a professor in The Wistar Institute’s Vaccine & Immunotherapy Center — the team has proven an exciting concept: that the common cholesterol drug fenofibrate can boost T cells’ ability to destroy human tumors, as described in their new paper, “Treatment with the PPAR? agonist fenofibrate improves the efficacy of CD8+ T cell therapy for melanoma,” published in Molecular Therapy Oncolytics.
MD Anderson at Cooper first in world to enroll patient in promising trial for metastatic melanoma
Researchers at MD Anderson Cancer Center at Cooper are leading the way in new approaches to treating advanced melanoma using tumor infiltrating lymphocyte therapy.
FDA Fast Tracks Naporafenib for Unresectable, Metastatic Melanoma
The Phase III SEACRAFT-2 trial will analyze the clinical efficacy of naporafenib compared with physician’s choice of single-agent dacarbazine, temozolomide, or trametinib among patients with NRAS-mutated metastatic melanoma who received prior treatment with an immunotherapy.
Efficacy Shown for New Melanoma Therapeutic Vaccine
FRIDAY, Dec. 15, 2023 (HealthDay News) — In a recent trial, a new melanoma vaccine, mRNA-4157 (V940), when taken in combination with Keytruda (pembrolizumab), was found to be effective in battling the deadly skin cancer.